




Analysis of Myelin-Reactive T Lymphocyte Function in 



























A thesis submitted for the Degree of Doctor of Philosophy 







I declare that this thesis has been composed by myself, describes my own work and 




































Firstly, I cannot thank my boss, Steve Anderton, enough for all the generosity, 
booze, leadership and guidance. I could never have gotten through this had you not 
helped me escape liposome hell but especially thanks for the times when you got 
tough. I’ll always regret the lack of karaoke.  
 
Thanks also to the occupants of Room 201. Claire ‘Swear Bear’ Sweenie, for 
mothering me through the early experiments - I’m not sure what I would have done 
without you – you rock my world. Richard ‘Dicky’ O’Connor, I’m going to miss 
your comic genius, you have been an absolute legend, my swami of snacks and my 
‘go-to’ guy. Chen-Yen, for being the nicest soldier I’ve ever met and for endless 
supplies of classic quotes. ‘Volder’Jo Konkel, for taking so much abuse over the 
years, crying only occasionally and giving us all so many memorable moments (red 
wine anyone?). Mel Leech, the lab ‘big sister’, for being down to earth (god knows I 
need it), for the times when you’re worrying about someone else and for always 
being prepared to help me out. Last but not least, my bench wench, Katy (with a ‘y’) 
Malpass: I’ll miss your weegie love, advice, rollockings, our hot ice-cream dates, 
motor boat days and getting hopped up and making some bad decisions - thanks for 
not judging me… too often. 
 
To the rest of my comrades in Team Anderton – Anne, Antonio, Cat, Dave, Kelli, 
Kristin, Leigh, Mandy…I salute you. To everyone in 3IR, I appreciate everything 
you’ve helped me with (special mention for Sheila & Bette). Thanks to Leslie, Stu, 
Al and the rest of the AW staff for the cracking, totally non-pc, banter. 
 
Thanks to my dad for inspiring me, to my mum and Shini for always being there and 
to all my brothers and sisters (especially Anks, Gogs and Rinks). 
 
Finally, thank you so very much to The Multiple Sclerosis Society for funding my 





















Immune tolerance to self antigens prevents the onset of autoimmune diseases such as 
Multiple Sclerosis (MS). There are three branches of tolerance which allow the auto-
aggressive potential of T lymphocytes to be limited; these are death, anergy-
adaptation and regulation.  
 
The main body of this work attempts to clarify a role for adaptation in maintaining 
the sensitivity of the autoreactive T cell repertoire below a ‘threshold for harm’ in the 
mouse model of MS, experimental autoimmune encephalomyelitis (EAE). The well 
defined myelin basic protein (MBP) Ac1-9 epitope altered peptide ligand (APL) 
system has been used to develop a model allowing the examination of mechanisms 
underlying the adaptation of cells. Previous data showed immunisation with the 4Lys 
(wild-type) epitope mediated disease whereas a superagonist APL with a tyrosine 
substitution at position 4 (4Tyr) did not, despite showing potency in vitro. This was 
shown to be a result of both activation induced cell death and adaptation. Here an in 
vitro model was developed using MBP-reactive TCR transgenic cells to make 
predictions about the mechanisms underlying adaptation. These data lead to the 
conclusion that T cells can adapt (become less sensitive) either before or after 
encounter with the wild-type peptide, leading to a reversal of their pathogenic 
potential. 
 
The MBP APL system and MBP reactive transgenic cells were also used to assess 
the contribution of epitope spreading in a relapsing-remitting (RR) model of EAE 
induced with proteolipid protein. The cells were tracked and changes in phenotype 
and behaviour were monitored. The data show that disease induced with one antigen 
can be manipulated with cells relevant to a different antigen and that bystander 
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The immune system consists of a highly synchronised system of layered defences 
whose combined purpose is to identify and eliminate foreign elements such as 
bacteria and virions from the host and to eradicate malfunctioning host cells. 
 
Physical barriers provide the first layer of defence; skin prevents the majority of 
infections, whilst sneezing and coughing can eject others. Many bodily secretions 
also carry antimicrobial agents, tears carry lysozymes and skin secretes β-defensins. 
 
The second layer is the innate immune system. This system serves to recruit cells to 
the site of infection through the release of chemical signals; it also activates the 
complement cascade. Within this system certain white blood cells, phagocytes, patrol 
the host to detect foreign matter, then eat and digest this matter. Other cells, dendritic 
cells (DC), are able to pick up foreign antigen and in response can release signalling 
molecules into the bloodstream. This brings us to another role of the innate system; 
the activation of adaptive immune responses. 
 
The adaptive immune response is the third tier of the immune system; it consists of 
bone marrow derived B and T lymphocytes and is activated by cells of the innate 
response which present foreign antigen to T lymphocytes. The presentation of 
antigen activates the T lymphocytes and allows them to produce cytokine signals 
which enhance the defensive properties of other cells. B lymphocytes detect antigen 
via antibodies on their cell surface and can process these to present to T lymphocytes 











1.1. Multiple Sclerosis 
 
Multiple sclerosis (MS) is the most common demyelinating disease of the central 
nervous system (CNS) in the developed world. It affects approximately one in 1000 
people in Europe, North America and Australasia, a total of around 2.5 million 
people worldwide [1, 2]. It is unknown whether MS is a result of environmental [3] 
or genetic factors (35% concordance in monozygotic twins [4]) , infectious agents [5] 
or a combination of all of these. The disease is characterised by ‘acute focal 
demyelination and axonal loss culminating in chronic multifocal sclerotic plaques’[2] 
and perivascular inflammation. The plaques locate to optic nerves, brainstem, 
cerebellum and spinal cord white matter, the location explaining clinical outcomes 
such as visual impairment and paralysis due to the loss of signal integrity between 
nerve cells in the CNS.  
 
MS is generally divided into two categories, relapsing-remitting (RR) and chronic-
progressive (CP). 80% of patients have the RR MS form which usually affects young 
adults in whom symptoms flare up for several days and the disease can go into 
remission for many years. With CP MS in all cases the symptoms continue to worsen 
without remission, however as the severity and timing is variable it is divided into a 
further 3 sub-categories; primary-progressive (PP), secondary-progressive (SP) and 
progressive relapsing (PR) [2, 6]. 
 
 
A single disease or various diseases with similar symptoms? 
 
The clinical symptoms of MS vary between patients and recent literature indicates 
that the various forms of MS may in fact constitute different diseases. This 
suggestion is supported by distinct categorisation of disease lesions into 4 pattern 
classes. Pattern 1 is macrophage mediated; 2 is both macrophage and antibody 
mediated and constitutes the highest number of cases; 3 shows distal 
oligodendropathology and apoptosis; 4 shows primary oligodendroglia degeneration 
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[7]. Patterns 1 and 2 are associated with T cell mediated encephalomyelitis whereas 3 
and 4 are associated with viral damage. Emerging candidates as an alternative 
diagnosis to MS appear to be Neuromyelitis Optica (NMO) and Balo’s Concentric 
Sclerosis (BCS). BCS lesions are typically pattern III lesions associated with 
increased inducible nitric oxide synthase leading to mitochondrial dysfunction and 
hypoxia like tissue injury [8]. NMO lesions show ‘rim’ and ‘rosette’ pattern II 
lesions in both the grey and white matter of the CNS. NMO can also be distinguished 
from MS by the presence of NMO-IgG which is absent in MS cerebrospinal fluid 
(CSF). This NMO-IgG targets the aquaporin-4 water channel (AQP4). AQP4 is 
manly found in the periventricular and periaqueductal areas of the brain and spinal 
cord and is concentrated at the astrocytic foot processes which line the outside of the 
blood brain barrier [9].  
 
 
Genetic Associations within MS 
 
The involvement of genetic factors in MS has long been proposed [10] and has been 
supported by the predominance of the disease in women over men [11] .  
 
The Human leukocyte antigen (HLA)-DR2 in chromosome 6 is represented at 
increased frequencies in MS and is therefore suggested to confer susceptibility to 
MS. The DR3 molecule has also been shown to be associated with CP MS [12]. 
Increasingly the question in MS appears not to be which genes are responsible for the 
disease but which genes are responsible for the various aspects of the disease. The 
strong linkage disequilibrium within the HLA has made pinpointing exact genes 
difficult. 
 
The first indication of a role for HLA-DR in the progression of MS came from 




To enable definition of gene function, Fugger and colleagues later developed a set of 
transgenic mice which feature HLA-DR2 elements (DRB1*1501 and DRB5*0101) 
and T cell receptor (TCR) (Hy2E11 TCR) from MS patients. These humanised mice 
contain either one or both of the HLA alleles. DRB1*1501 mice show clinical signs 
of severe disease whereas DRB5*0101 mice do not develop disease. The addition of 
the *0101 to the *1501 reduces the severity and the incidence of disease. This 
suggests that in humans where both elements are present the *1501 is the causal gene 
and that *0101 acts as a genetic modifier. The *0101 causes apoptosis in disease 
relevant T cells and therefore can be considered an implement of peripheral tolerance 
[14]. 
 
Other specific risk alleles were identified in a DNA micro-array analysis of 931 
family trios. This study confirmed that 57% of those screened had the HLA-
DRB1*1501 allele. Other alleles identified as having a significant association with 
MS encoded the IL-2R α chain (CD25) and the IL-7Rα chain. Any impact on IL-
2Rα may have an effect on CD4+CD25+ Regulatory T cells and therefore on 
peripheral tolerance. IL-7 has an effect on homeostasis of the T cell memory pool 
and potentially a role in generating autoreactive T cells [15]. 
 
 
Current therapies for MS 
 
Many potential treatments have been applied to MS, however there is no cure 
currently available and the two best known licensed treatments are Beta Interferon 
and Copaxone. Trials with Campath-1H are currently taking place. 
 
The beta interferons (Interferon β1a and β1b) were the first drugs approved for use in 
cases of RR MS and are known to reduce the destructive activity of IFN-γ. Beta 
interferon reduces relapse rates as well as slowing the accumulation of disability. 
However recent reports have indicated that due to the action of anti-beta interferon 
antibodies the efficacy of this drug is reduced in some patients [16].  
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Glatiramer acetate (Copaxone) is a synthetic amino acid co-polymer which is made 
up of L-alanine, L-lysine, L-glutamic acid and L-tyrosine in a similar molar ratio as 
they would be found in MBP. It has similar effects to beta interferon. It is suggested 
that Copaxone exerts its effects by inducing a T helper (Th) 2 cell response to 
combat the Th1 response which mediates disease [17]. Some studies suggest that it 
may also competitively bind MHC molecules thereby preventing self antigens from 
binding [18]. 
 
Campath-1H is a rat monoclonal antibody which was humanised and developed to 
treat human malignancies by lysing T lymphocytes [19]. It targets the CD52 antigen 
(integral membrane protein used in signal transduction) on lymphocytes and 
mediates sustained T cell depletion through either complement or cell mediated 
cytotoxicity. Campath-1H is much more powerful than the other drugs available 
because the CD52 antigen is expressed on a wide range of immune system cells 
including all lymphocytes, DC and macrophage.  
 
Rituximab (IDEC-C2B8) is known to target the CD20 transmembrane 
phosphoprotein that is expressed only by pre-B and mature B cells. This genetically 
engineered chimeric murine / human IgG1 kappa monoclonal antibody binds 
complement and therefore can mediate B cell lysis [20]. Originally this drug was 
developed as an alternative to chemotherapy treatment non-Hodgkin’s Lymphoma 
and was the first licensed monoclonal antibody used to treat cancers [21]. Clinical 
results from studies using Rituximab have shown significant decreases in B cell as 
well as T cell (55% decrease) levels. The B cells were eliminated for up to 9 months 
after therapy (not memory B cells however as they express no CD20). A 
disadvantage of the use of this drug is that it may not be effective in combination 
therapy, its use alongside beta-interferon showed the emergence of anti-beta-
interferon antibodies despite the apparent depletion of B cells. 
 
Natalizumab is another more recent addition to the drug arsenal against MS. It is a 
monoclonal antibody directed against the adhesion molecule VLA-4. VLA-4 
expression is required by T cells to migrate from the peripheral lymph nodes, across 
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the blood brain barrier and into the CNS. The use of natalizumab alone showed 
dramatic reductions in relapse rates per annum, this reduction was similar to that 
seen when natalizumab was used in conjunction with beta-interferon implying that 
combination therapy was no more effective than natalizumab alone. However in two 
cases (from 1000) severe progressive multifocal leucoencephalopathy was seen due a 
JC virus infection [22]. 
 
Fingolimod (FTY720) is an immunomodulatory drug which down-regulates the 
expression of sphingosine 1-phosphate receptor. This has the effect of sequestering 
mature T lymphocytes within the secondary lymphoid tissues and thymus thereby 
preventing their migration into the CNS. This is confirmed by histological data 
which shows a reduction in the number of plaques within sick mice treated with 
FTY720 compared to those that are not treated. The plaque being a result of and 
therefore an indicator of T cell infiltration into the CNS [23]. 
 
 
1.2. Experimental Autoimmune Encephalomyelitis (EAE) 
 
EAE is the animal model of choice to study MS. EAE has its origins in the 
observations at the turn of the 20
th
 Century that a small number of people, who had 
been vaccinated against rabies, were showing signs of paralysis. In 1905, Remlinger 
[24] postulated the disease to be a result of CNS tissue contaminating the vaccine. In 
1928, Stuart and Krikorian reported that when rabbits were repeatedly inoculated 
with human spinal cord or sheep’s brains that the treatment occasionally resulted in 
paralysis [25].  
 
Later, spurred by his own recurring incidences of muscular atrophy [26], Rivers 
showed that demyelinating disease was inducible in primates using injections of 
rabbit CNS [27]. Rivers used as many as 50-80 injections of CNS tissue before he 
observed a result. Later studies showed that a single administration could be used if 
accompanied by complete Freund’s adjuvant (CFA) [28].  With advances in the 
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understanding of the myelin sheath we are now able to induce EAE with specific 
myelin antigens in conjunction with CFA and Pertussis Toxin (PTx); this is known as 
the active induction of EAE. 
 
Lymphocytes have been known to play a central role in the dissemination of MS and 
EAE model since Paterson’s experiments in the 1960s which showed that lymph 
node cells could transfer disease between rats [6, 29, 30]. Paterson’s work was also 
the first description of the passive induction of EAE however this programme of 
work did not clarify the group of lymphocytes responsible for the manifestation of 
disease. 
 
T cell dependency of disease was shown in experiments using thymectomised 
irradiated rats reconstituted with either normal lymphoid cells or those depleted of T 
cells (by treatment with anti-rat thymocyte serum) from mice previously challenged 
with MBP and CFA. Non-manipulated cells potentiated normal EAE and antibody 
production whereas depletion of T cells resulted in the prevention of EAE and the 
ablation of antibody production [31] .Later work blocking T cell surface molecules, 
such as CD28 and CD40L, with antibodies and the depletion of CD4
+
 post induction 
of EAE has also shown the central role of firstly T cells and then CD4
+
 cells within 
the progression of the disease [32-34].  
 
Today passive transfer EAE experiments are conducted by the adoptive transfer, into 
naïve mice, of T cells isolated from myelin antigen primed mice. The CFA used in 
the active model of EAE contains Mycobacterium tuberculosis which aids the initial 
development of an immune response upon administration with the relevant myelin 
antigen. The passive model is advantageous because it bypasses the need for the 
introduction of non-disease relevant antigen. 
 
Although the EAE disease model has been replicated in many animals, the pattern of 
disease progression and the histopathology varies significantly between each species. 
All models share a destruction of the myelin sheath, lesions in the CNS and the 
presence of immunoglobulin in the CNS and cerebrospinal fluid [35].  
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EAE shares many of the characteristics of MS, including the widespread foci of 
inflammation and demyelination accompanied by perivascular infiltration of 
mononuclear leukocytes. Disease course is often monophasic but can also have 
relapsing and chronic phases depending on the antigens and species used to induce 
disease.  
  
It must be noted that EAE is not MS nor is it a perfect model of MS. However the 
various models of EAE are useful in representing various aspects of MS. 
 
 
1.2.1. Identification of Myelin Autoantigens 
 
Three major autoantigens involved in MS and EAE have been identified; Myelin 
basic protein (MPB) [36], proteolipid protein (PLP) [37] and myelin oligodendrocyte 
glycoprotein (MOG) [38]. These CNS antigens have been relatively hard to isolate 
because of the high lipid content of the myelin sheath. 
 
MBP, discovered in 1962 by Einstein et al, is a major protein constituent of the 
myelin sheath (around 30%) and is expressed both in the central and peripheral 
nerves. EAE can be effectively induced with MBP and adjuvant in a wide range of 
animal models [30, 36, 39]; most work in EAE has been done on MBP due to its ease 
of isolation. 
 
PLP makes up 50% of the myelin sheath protein and because of its hydrophobicity 
interacts with myelin lipids and is also difficult to purify. This hydrophobic nature of 
this integral membrane protein means that it is difficult to work with due to 
insolubility [40-42].  
 
MOG composes less than 0.05% of the myelin sheath protein, however it induces 
EAE in many strains and species of animals [43]. It has been suggested that the 
severity of the disease caused by MOG may be due to the accessibility of the protein 
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to antibodies, therefore MOG induced disease may be antibody and complement 
mediated [40].  
 
The phenotype of disease depends on the peptides used to induce EAE; the lesions in 
MBP and PLP induced disease are seen primarily in the spinal cord whereas those 
from MOG induced disease are seen in optic nerves as well as in the spinal cord [43]. 
As discussed later, T cells recognise short peptide sequences (9-11 amino acids), 
generated by antigen processing, displayed on MHC class II molecules. Epitope 
mapping studies have allowed the identification of distinct T cell epitopes that are 
able to mediate disease.  
 
The first myelin protein in which an encephalitogenic region was defined was MBP 
[44] in experiments using synthetic peptides to induce EAE in guinea pigs. Evavold 
& Allen used analogue peptides with amino acid substitutions within this model to 
demonstrate the requirement for single residues in disease progression and thereby 
essentially created the first altered peptide ligands (APLs) [45]. It was more than a 
decade later that Zamvil and colleagues were able to identify the most commonly 
used murine encephalitogenic region of MBP, the n-terminus Ac1-9 epitope on H-2
u
 
MHC genetic backgrounds [36].  
 
Later studies in H-2
s
 (SJL) mice identified the encephalitogenic PLP139-151 sequence 
[41] as well as the MOG92-106 [46]. The identification of the MOG35-55 sequence 
allowed for the expansion of EAE studies into the C57BL/6 murine strains [47]. This 
has allowed the expansion of studies into EAE using well developed gene knockout 
and transgenic variants of the C57BL/6 mouse. 
 
The identification of sequences with the potential to help induce autoimmune 
pathogenicity enables the induction of EAE with synthetic T cell epitopes, CFA and 
PTx. Synthetic peptides have also helped to overcome the problem of isolating 




1.2.2. TCR Transgenic Models of EAE 
 
The use of TCR transgenic mice has helped to overcome the problem of limited 
numbers of disease relevant cells in many models including EAE [48]. Paradoxically, 
in some transgenic mice, the large number of these antigen-relevant cells leads to 
poor T cell activation, upon challenge, due to competition between the TCRs to bind 
to MHC.  
 
The Tg3 and Tg4 models constructed by Liu  et al [49] have an encephalitogenic 
TCR, on the B10.PL (I-A
u
 )background, which recognises the encephalitogenic 
MBPAc1-9 peptide. Created from a MBPAc1-9 reactive T cell clone, all the Tg4 CD4
+
 
cells were found to have the Vβ 8.2 chain [50]. These mice require immunisation 
with peptide before EAE could be induced.  
 
The transgenic mouse relevant to MOG35-55 is the 2D2, made by Betelli et al. The 
TCR in this model consist of  a Vα3.2 and Vβ 11 on the I-Ab (C57BL/6) background 
[43]. However studies in our group have suggested that these mice have cells 
deficient in being able to cross the blood brain barrier and are deficient in inducing 
effective disease in some murine strains of the same background (unpublished 
findings). 
 
A transgenic mouse for PLP was created using T cell clones, derived from SJL mice, 
which expressed TCR carrying Vα4 and Vβ6. They respond to PLP139-151 on the I-A
s
 
background. These mice developed spontaneous EAE with too great a frequency to 
be maintained on the SJL background [51]. 
 







1.3. Theiler's Murine Encephalomyelitis Virus (TMEV) 
 
TMEV is an endogenous mouse pathogen which targets antigen presenting cells 
(APC), in particular quiescent microglia, in order to establish a persistent, life-long, 
infection in the CNS APCs; this infection results in up-regulation of the innate 
immune response accompanied by the production of cytokines to activate T cells and 
cell surface receptors facilitating antigen presentation to T cells [52]. 
 
In SJL mice, infection with the wild-type TMEV disease develops between 4 – 5 
weeks post-infection. TMEV relevant Th1 cells target the virus in the CNS and 
produce pro-inflammatory cytokines which activate macrophages. These activated 
macrophages cause bystander damage to the CNS resulting in a breakdown in the 
myelin sheath and immune responses are directed to myelin epitopes via epitope 
spreading. T cell proliferative responses to the viral epitope are seen within 14 days 
of infection and last through to at least day 90. Responses to PLP epitopes are seen 
around day 50 post-infection and subsequently spread to other myelin epitopes as 
myelin sheath damage is increased. 
 
Miller et al developed a molecular mimicry model of MS by engineering a non-
pathogenic variant strain of TMEV encoding a 30-mer peptide incorporating the 
PLP139-151 epitope. Infection with this PLP-TMEV reduces the onset of disease to a 
week; autoreactive Th1 cells are rapidly directed to the CNS and initial myelin 
damage is followed by epitope spreading resulting in a relapsing-remitting disease 
[52, 53]. Building on this and on earlier work by Carrizosa et al [54], Miller’s group 
engineered another variant TMEV to further illustrate the potential of molecular 
mimicry in disease induction. These experiments used TMEV encoding a 
Haemophilus influenzae mimic peptide (HI574-586) which shared only 6 of the 13 
amino acid residues of PLP139-151 [53] including the primary TCR and MHC contact 
residues. 
 
Mice infected with this virus exhibited early onset of disease and a cross-reactive 
CD4+ T cell response to PLP139-151. When emulsified with CFA, HI574-586 fails to 
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induce demyelination in the CNS of SJL mice even when administered several times. 
The fact that the combination of TMEV and HI574-586 can cause disease highlights the 
role of a ‘natural’ infection in the induction of autoimmune disease via molecular 
































 T cell Activation 
 
T lymphocytes act to direct the adaptive immune response by working as antigen 
receptor bearing cells in synchronisation with APC. This relationship is essential for 
the clonal expansion of T lymphocytes and progression into effector T cells [56]. In 
order to facilitate this interaction the immune system is required to arrange an 
encounter between one of 1 in 100,000 (approximately) peptide-relevant T cells and 
an APC presenting the relevant peptide in association with MHC molecules [57].  
 
Naïve T cells mainly recirculate through the blood and the secondary lymphoid 
tissues. The expression of chemokine receptors (CCR7) and adhesion molecules 
(CD62L) directs the circulation between the secondary lymphoid tissues through 
migration across the high endothelial venules (HEV). On entry to the LNs, T cells 
are attracted by chemokines (e.g. SLC/CCL21, the ligand for CCR7) to the T cell 
areas where they undergo multiple short encounters with DC and scan for antigen. If 
no antigen (foreign or domestic) is present the T cells remain in the nodes for up to 
20 hours and then re-circulate [58].  
 
Upon antigen presentation CD44 (adhesion molecule) and CD69 expression is up-
regulated and T cells slow down and have been observed to make longer contacts 
with DC. T cells also produce IL-2 and CD25 (the IL-2 Receptor α-chain) although 
no proliferation takes place [59]. With the up-regulation of CD25 the cells become 
more responsive to IL-2. This phase lasts between 8 and 24 hours. At 24 hours rapid 
proliferation of antigen-relevant T cells is seen and although the progeny express less 
CD25, CD69 and CCR7; CD44 remains high [60]. The activated cells start to express 
other chemokine receptors which enable migration of the cells to the lymph node 





1.4.1. Requirements for T cell Activation 
 Signal 1 and Signal 2 
 
To enable the activation of CD4
+
 T lymphocytes, two signals are required; Signal 1 
is provided through the interaction between the T cell receptor complex and peptide 
presented within the MHC Class II groove on the surface of an APC.   
 
Signal 2 also provided by the APC is mediated by the cross-linking of CD28, leading 
to T cell activation and proliferation [61]. Further work identified B7 molecules 
(CD80 and CD86) as ligands for CD28 [62]. The CD28 signal is required for the 
production of IL-2 that drives T cell proliferation [63, 64]. Cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) is known to act with CD28; CTLA-4 has a greater 
affinity for B7 and through competitive binding it induces an inhibitory effect on 
signalling.  
 
Von Boehmer postulates three theories as to the function of CTLA-4 based on its 
interaction with the B7 molecules: (1) naturally occurring regulatory T cells (nTregs) 
may interact with effector cells at an APC and then either act directly with the 
effector cell or through the APC. (2) Suppressor cells may not be present at all and 
effector cells may suppress each other through CTLA-4 and B7 interaction. (3) In 
APC mediated suppression, the suppression of effector T cells would appear to be 
the result of the up-regulation of indoleamine 2,3-dioxygenase (IDO) which 
metabolises tryptophan, an amino acid required for T cell activation [65]. 
 
Further research has shown that co-stimulation is far more complex than simply the 
interactions between CD28 and B7; there are many other costimulatory or accessory 
molecules involved. There are now suggested to be two main groups of 
costimulatory molecules; the immunoglobulin superfamily (including CD28 and 
CD2) and the tumour necrosis factor-R superfamily (OX40, CD137 and CD27) [66]. 
This latter group are all shown to boost the production of cytokines and proliferation 
of reactive T cells when cross-linked. For example, OX40 deficient T cells have 
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reduced proliferation and undergo apoptotic cell death at days 4-5 after activation 
because OX40 controls the anti-apoptotic BCL-2 family of molecules [67] [68] . 
 
Adhesion molecules, such as CD58 (CD2 ligand) [69] and ICAM-1 (LFA-1 
ligand)[70] are also known to be able to contribute to Signal 2 and in turn allow the 
formation of the immune synapse. The need for prolonged cell contact through cell 
adhesion molecules is magnified by the slow binding kinetics of the TCR-peptide-
MHC interaction [69]. The presence of Signal 1 alone results in T cell anergy or 
death in vitro and tolerance in vivo [71]. 
 




Signal 3 is a reference to signals that are transmitted from the APC to the T cells 
which determine the naïve T cells path of differentiation into three main effector T 
cell groups, Th1 cells, Th2 cells or Th17 cells. Signal 3 is transmitted through the 
production of cytokines by the APC; the cytokine milieu that is created dictates 
which subset the T cells belong to and which combination of cytokines the T cell 
itself will release upon activation (Figure 1.1). 
 
IL-12 is an example of a cytokine, released by DC, which is able to deliver signal 3 
and promote Th1 cell expansion. The Th1 subset is characterised by the production of 
tumour necrosis factor alpha (TNF-α) and IFN-γ. IL-12 augments the production of 
IFN-γ which up-regulates MHC Class II and co-stimulatory molecule expression by 
microglia and astrocytes [72] and thereby increases the presentation of myelin 
antigens to cytotoxic T cells. IL-12 also promotes the expression of the IL-18 
receptor which again aids to promote the production of IFN-γ. IL-4 promotes the Th2 
phenotype characterised by production of IL-4, IL-10 and IL-13. [6, 73-76]. 
 
Despite EAE appearing to be the prototypic Th1-driven disease, IFN-γ deficient mice 
have been shown to be susceptible to a more progressive form of EAE with large 
inflammatory infiltrates in the CNS [77]. Initially these findings were supposed to be 
a result of the regulatory functions of IFN-γ  [78] or its ability to induce apoptosis in 
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reactive T cells[79]. In addition, the injection of  IFN-γ during chronic inflammation 
is known to block EAE [80]. The answer to why IFN-γ deficient mice suffer from 




In 2003, Aggarwal et al [81] showed that IL-17 production was enhanced from 
memory CD4
+
 cells but not from naïve CD4
+
 cells by the actions of IL-23. IL-23 was 
shown to be composed of the p19 and p40 subunits, the latter which it shares with 
IL-12. The p35 subunit of IL-12 is not shared however and this explains the findings 
that IL-12p35 deficient mice were previously observed to be susceptible to EAE [82] 
whereas p40 deficient mice were resistant to disease induction [83]. 
 
IL-23 is secreted by activated macrophages and DC [84] and Langrish et al [85, 86] 
suggest IL-23 acts on previously activated cells (before their final differentiation to 
Th1 phenotype) to generate a Th17 subset. The suggestion of this subset had already 
been made in 2000, when it was observed that naïve T cells primed with B. 
burgdorfei lysates produced larger amounts of IL-17A than T cells primed under Th1 
and Th2 conditions [87]. This model would predict that T-bet expressing (pre-Th1) 
cells would express both IL-12R and IL-23R on their surfaces and depending on the 
cytokine milieu would differentiate into Th1 or Th17 cells. 
 
Distinct roles for both Th1 and Th17 subsets are suggested by the factors they express; 
IL-23 polarised cells express high amounts of IL-17A and IL-17F as well as TNF-α. 
IL-12 polarisation of cells promoted the expression of IFN-γ, granzyme F, granzyme 
G, TNF-related apoptosis inducing ligand (TRAIL) and FAS ligand. A role for IL-17 
was confirmed when EAE was induced by the passive transfer of IL-17 producing 
CD4
+
 cells [85]. 
 
A key function of T cells in EAE appears to be the activation of macrophage. These 
cells are activated by IFN-γ; they in turn produce pro-inflammatory mediators 
including IL-1, IL-6, Nitric Oxide (NO) and TNF-α [88] as well as being involved in 
complement and antibody induced phagocytosis [89].  
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TNF-α has been shown to both mediate and control levels of inflammation [12]. It 
has cytotoxic effects on oligodendrocytes in the CNS that leads to apoptosis [90]; it 
also promotes the production of NO from macrophage that mediates further damage 
to these cells and causes demyelination [91]. Human studies show that the 
administration of anti-TNF-α antibodies results in immune activation. However in 
some animal models, these antibodies have been shown to ameliorate EAE possibly 
due to auto aggressive T cell apoptosis induction [92]. IL-1β [93] and IL-6 [94] are 
both shown to induce glutamate. Glutamate is a neurotransmitter which in excess 
causes neuronal cell death [88] and hence damage in the CNS.  
 
IL-10 inhibits Th1 cell proliferation as well as limiting Th1 cytokine production. It 
also act on macrophages to prevent the production of pro-inflammatory cytokines, 
down-regulate MHC class II and co-stimulatory molecules [95]. Perhaps more 
importantly, the presence of IL-10 during T cell activation results in anergy or non-
responsiveness in treated cells [96]. IL-10 deficient mice have been shown to 
develop a more severe form of EAE than wild-type mice and the T cells from these 
mice undergo greater antigen-specific proliferation and cytokine production when 
stimulated ex vivo [97]. IL-10 can be produced by TR1 cells [98] or by B cells. The 
Anderton group have used B cell chimeric mice, in which the B cell compartment 
was IL-10 deficient, to show that disease recovery is impaired despite the presence of 
IL-10 from other sources [99]. 
 
Another cytokine implicated in the remission stage of EAE is transforming growth 
factor β1 (TGF-β1). The administration of TGF-β1 blocking antibodies increases the 
severity of disease whereas the administration of TGF-β1 ameliorates disease [100]. 
 
The signals received by the TCR, co-stimulatory molecules and cytokine receptors 
are collated to initiate the differentiation of naïve T cells into the various subsets. Th1 
polarisation is a result of the action of IFN-γ on signal transducer and activator of 
transcription 1 (STAT1) [101]. This, together with TCR signalling events, results in 
the up-regulation of the T-box transcription factor T-bet in naïve T cells [102]. T-bet 
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induces IFN-γ and has also been shown to induce chromatin remodelling of the gene 
encoding IFN-γ [103].  
 
The actions of IL-4 on STAT6 result in the polarisation of naïve T cells to the Th2 
phenotype [104]. This results in the selective expression of c-MAF, a member of the 
basic-region leucine-zipper family [105] and GATA3 [106]. The former is known to 
transactivate the IL-4 promoter [105] whereas the latter transactivates the IL-5 
promoter [107]. 
 
The recently discovered Th17 lineage is dependent on STAT3 and STAT4. TGFβ1 is 
always required to signal through STAT3 but it retains the flexibility to work in 
association with either IL-6 from DC or IL-21 from NK cells to differentiate the 
naïve T cells into Th17 cells [108]. For the transduction of signals through STAT4, 
TGF-β must work with IL-23 [109]. The transcription factor RORγt has also been 
identified as being specifically expressed in Th17 cells and as a regulator of Th17 
differentiation. Mice lacking RORγt were shown to have a less severe course of 

















































1.4.2. Molecular Basis of T cell Recognition 
 
The specificity of a T cell is determined by its clonotypic TCR. The TCR molecule 
consists of an α and a β polypeptide chain, each containing a variable (V) and 
constant domain. The V chain uses complementary determining regions (CDRs) to 
achieve variability between TCR; CDR1 and CDR2 through the germ-line and CDR3 
through somatic mutation [111]. These variable regions on CD4
+
 T cells recognise 
antigenic peptide bound within the groove of an MHC Class II molecule. The 
binding groove of the Class II heterodimer (α and β chains) consists of the floor 
(beta-pleated sheet) and the walls (α helices). The binding grove of the Class II 
molecule has open ends allowing the binding of peptides of variable length (10-15 
amino acids) [112].  
 
Several ‘pockets’ within the binding groove determine which peptides can bind. 
Peptides need only contain two or three critical amino acid residues (a motif) 
correlating with the pockets in order to bind to a given MHC class II molecule [113]. 
Allotypic variation in the peptide binding grooves of different class II molecules 
determines which peptide will bind which MHC molecule and is central to MHC-
restriction in T cell reactivity. With the peptide bound between the MHC class II, the 
TCR positions itself so that the CDR1 and CDR2 are over the N- and C- termini of 
the peptide and interacting with the HLA α and β chains [114, 115]. The CDR3 
chain interacts with the peptide to determine the specificity of the interaction [116]. 
In humans the MHC class II loci within HLA complex are DP, DR and DQ 
homologues in the mouse are the I-E and I-A H-2 gene loci respectively. 
 
In nearly all autoimmune diseases susceptibility to disease is associated with certain 




 T cells recognise peptides in the context of MHC class II. Although many cell 
types can express MHC class II under extraordinary conditions, the true APC are B 
cells, macrophages and DC, since their MHC class II expression is constitutive. In 
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addition to signal 1 APC must provide signal 2 (costimulation). The three types of 
APC vary in their ability to provide both signals 1 and 2.  
 
These cells are able to uptake antigen via receptor mediated endocytosis, 
phagocytosis and macropinocytosis. Proteins must be processed to provide peptide 
fragments for MHC class II loading. Antigen processing is facilitated by a battery of 
proteases within the endocytotic pathway. MHC class II peptide loading occurs in 
low pH endosomal compartments [116] by removal of the CLIP peptide which 
protects the MHC class II binding cleft during biosynthesis. MHC class II is known 
to recycle from the plasma membrane allowing the opportunity for possible peptide 
exchange at, or close to, the cell surface. 
 
B cells are inefficient at antigen uptake unless it is via their antigen-specific surface 
immunoglobulin (Ig) receptors. The binding of antigen to these receptors leads to 
internalisation of the receptor followed by rapid presentation of the peptide on MHC 
class II. This means that the B cells can uniquely focus on presenting specific 
antigens to elicit T cell help during the humoral response. B cells are also aided in 
their presentation capability by the high expression of MHC class II and 
costimulatory molecules upon activation [118].  
 
B cells have the potential to influence the progression of EAE via 3 mechanisms; 
they can produce pathogenic autoantibodies; they can act as APC, as described 
above, to activate auto-aggressive T cells; or they can play a role in mediating 
recovery from disease (discussed later). The APC function of B cells has been the 
subject of much scrutiny; initial experiments in which mice were depleted of B cells, 
using anti-µ antibodies, suggested that B cells were required as both APC and 
producers of anti-MBP antibodies in the development of EAE induced with MBP 
[119]. Later studies with µMT (B cell deficient) mice showed that B cells were not 
required for induction of disease when the mouse MOG35-55 antigen was used to 
immunise but were required for induction if intact recombinant human MOG protein 
was used to immunise [120, 121]. Differences in amino acid sequences between 
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human and mouse MOG protein may account for differences in B cell recognition 
and therefore differences in disease induction. 
 
Macrophages are particularly well adapted to endocytosis but their low expression of 
MHC class II and costimulatory molecules makes them inefficient at activating naïve 
T cells. However these can be up-regulated by stimulation with cytokine or bacteria 
[118]. Macrophages may therefore be key APC at effector sites during infection and 
inflammation. 
 
The term dendritic cell was first coined by Steinman and Cohn in 1973 [122]. These 
cells  can be considered the ‘professional’ APC because antigen presentation for the 
activation of T lymphocytes appears to be their primary function and, although other 
APC can help to magnify an ongoing T cell response, only DC have the ability to 
initiate new T cell responses.  
 
They are generated from either myeloid or lymphoid bone marrow progenitors and 
exist in two main forms, immature and mature.  In order for a T cell immune 
response to be initiated, the T cell (which circulates in blood) must find and 
recognise antigen (foreign or self) from anywhere in the body; it must also undergo 
expansion. However the majority of infected tissues are unable to provide the Signal 
2 required for expansion [123].  
 
Immature DC (such as Langerhans cells) act as sentinels in the peripheral tissues, 
such as the epidermis, where antigen is most likely to be encountered [124]. 
Immature DC express very little in terms of MHC class II and co-stimulatory 
molecules. However they do express a large number of antigen-capturing Fcγ and 
Fcε receptors [125] as well as C-type lectins which mediate endocytosis. The 
combination of antigen capture and macropinocytosis is so efficient that nanomolar 
concentrations of antigen are enough to elicit a response [126]. DC activation (for 
example by toll like receptor -TLR- ligation by pathogen-derived molecules) leads to 
their maturation to potent APC (i.e. increased MHC Class II and costimulatory 
molecule expression). These mature DC travel to the T cell areas of the lymphoid 
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organs where they release chemokines attracting T and B cells [127]. They then 
present antigen derived peptides to T cells to initiate T cell activation [128].  
 
DC are not restricted to interactions with T cells and are known to interact with both 
NK cells as well as B cells. There are many roles assigned to DC, some opposing and 
too diverse for the same cell to carry out. There needs to be different subsets of DC 
which carry out the different roles and there are two models which can be used to 
explain the generation of these subsets. The functional plasticity model suggests that 
all DC are members of the same haematopoietic lineage but the ‘plastic’ end product 
cell can be polarised into different subsets depending on the immediate milieu. The 
specialised lineage model suggests that subsets are the result of a lineage separation 
at the haematopoietic stage and subsequent divergences in the development pathway 
[129]. 
 
Distinct DC subsets were originally defined based on the expression of CD11c (the 
integrin αX chain). However more recently these subsets have been defined as 
myeloid DC (mDC), plasmacytoid DC (pDC),CD8α+ DC and Langerhans cells [129-
131].  
 
mDC have a monocytic morphology and are know to express markers such as CD13, 
CD33, CD11c and CD11b (the integrin αM chain of Mac-1) [132] and produce large 
amounts of IL-12 hence promoting Th1 cells [133]. 
 
pDC are so named because their morphology is similar to B lineage antibody 




, Gr-1, 120G8, CD4
hi
, CD62L 
and CD123 [131, 134]. pDC were also known as interferon producing cells (IPC) 







1.4.3. T Cell Receptor Signalling  
 
Following TCR engagement of a relevant peptide-MHC Class II complex, 
conformational changes occur between the TCR and CD3 molecules (Figure 1.2). 
The Src family leukocyte-specific protein tyrosine kinase (Lck) phosphorylates the 
immunoreceptor tyrosine-based activation motifs in the TCR-associated CD3 chains 
with family member Fyn. This establishes a binding site for the Src homology (SH2) 
domain of the tyrosine kinase Zap-70 (-chain-associated protein kinase of 70Da). 
Lck then phosphorylates and activates Zap-70 [136].  
 
In turn this activated Zap-70 phosphorylates the scaffold protein LAT (linker of 
activated T cells) and SLP-76. LAT provides a surface for the interaction of 
signalling components responsible for the propagation and dissemination of the T 
cell signal. Around the same time growth factor receptor-bound protein 2 (GRB2) 
binds via its N-terminal SH3 domains to the Son of Sevenless (SOS) guanine 
nucleotide exchange factor (GEF). Along with phospholipase C-γ1 (PLC-γ1), the 
GRB2 / SOS complex are subsequently recruited to the membrane linked LAT where 
they are activated by SLP-76 (SH2-domain-cointaining leukocyte protein of 76Da) 
[137].  
 
The GRB2 / SOS is used by Ras-GDP to allow a guanine nucleotide exchange to 
convert to its active form Ras-GTP. Once Ras is activated it recruits and activates 
Raf-1 (serine/threonine kinase) which in turn phosphorylates and activates MEK 
(MAPK/Erk kinase) [138]. This tyrosine/threonine kinase in turn phosphorylates and 
activates extracellular signal related kinases 1 and 2 (Erk1 and Erk2). These kinases 
initiate a MAP (mitogen-activated protein) kinase cascade which induces and 
activates Fos, a component of the AP-1 transcription factor [139].  
 
PLC-γ1 is activated by SLP-76 to cleave the phosphatidylinositol-4,5-biphosphate 
(PIP2) into diacylglycerol (DAG) and inositoltriphosphate (IP3) [140]. IP3 acts on 
the receptors on the endoplasmic reticulum to allow an increase in intracellular 
calcium concentration. The effect of this is activating calmodulin which activates the 
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serine phosphatase calcineurin. Calcineurin dephosphorylates the NF-AT (nuclear 
factor of activated T cells) transcription factor. In association with calcium, DAG 
activates protein kinase C (PKC) isozyymes including PKC−θ which activates the 
nuclear factor kappa B (NF-κB) transcription factor. DAG also recruits the RASGRP 
(RAS guanyl-releasing protein) nucleotide exchange factor which helps activate the 
ERK pathway and therefore activates the AP-1 transcription factor [141].  
 
AP-1, NF-AT and NF-κB act together to induce gene transcription which leads to 
cell proliferation and differentiation. [142]  
 
The signalling events above can be regulated by various protein tyrosine 
phosphotases. The first of these to have been identified was CD45 [143] which 
rapidly activated Lck in T cells by dephosphorylating its negative-regulatory site 
[144]. CD45 has many other positive effects on signalling including the activation of 
phospholipase C and mobilisation of calcium [145, 146]. 
 
Tyrosine phosphatase-2 (SHP-2) and LMPTP also are known to have a positive 
regulatory effect on T cell signalling. SHP-2 is known to enhance the activation of 
both RAS and MAPK [147]. LMPTP dephosphorylates the negative-regulatory site 
of Zap-70. If this site is allowed to be phosphorylated then it becomes a binding site 
for CBL (casitas B-lineage lymphoma) E3-ubiquitin-ligase complex which causes 
the internalisation and degradation of TCR – thereby downregulating TCR signalling 
(discussed further in Section 1.5.2) [148]. Other E3 ubiquitin ligases such as SLIM 
(STAT-interacting LIM protein) [149] and Deltex1 [150] have been shown to 
negatively regulate T cell signalling whereas positive regulation is seen with E3 
ubiquitin ligase TRAC1 (T cell RING protein identified in activation screen 1) [151]. 
 
LAT has also been shown to interact via GRB2 with the adaptor protein GRB2-
associated binding protein 2 (GAB2). This enables the recruitment of tyrosine 
phosphatase-1 (SHP-1) which in turn down-regulates T cell activation by 
dephosphorylating Zap-70 [152]. Another molecule, CD5, which negatively 



































1.5. T Cell Tolerance 
 
The number of different peptides that can be generated and presented far outweighs 
both the number of different TCR that gene segment recombination allows and the 
total number of T cells within a mouse. As a result if individual T cell recognised 
only one peptide, we would still be left short. This inequality in numbers leaves no 
option other than to have a cross-reactive TCR repertoire; otherwise the immune 
system may not recognise the many pathogens that can infect the host. Even with this 
TCR promiscuity Don Mason predicted that each naïve CD4
+
 cell must have the 
capacity to react with almost half a million different 11-mer peptides [153, 154].  
 
This ‘cross-reactivity’ has a flipside; in maintaining its ability to mount an effective 
response to a wide range of foreign antigens the TCR also retains the ability to react 
to a wide range of self antigens. This is why the immune system must eliminate self-
reacting T lymphocytes [155]. It must learn to be ‘self-tolerant’. The failure of 
tolerance can often lead to autoimmune pathology. 
 
1.5.1. Central Tolerance 
 
Kappler et al showed self–reactive T cells were present amongst immature 
thymocytes but were ‘severely depleted’ amongst mature thymocytes, hence showing 
that clonal elimination occurs in the thymus [156]. This elimination is termed 
‘central tolerance’ and serves as the primary route of limiting the cross-reactivity of 
the T cell repertoire.   
 
The mechanisms behind central tolerance and the selective pressures on T 
lymphocytes during thymic development are thought to be based on an avidity model 
of T cell activation. Avidity is described as the number of peptide-MHC (pMHC) 
complex engaged TCR per T lymphocyte. The primary factor determining avidity is 
the intrinsic affinity of the TCR for the pMHC complex. The density of the TCR and 
the density of the pMHC complexes are also factors [157]. The functional T cell 
avidity can therefore be defined as the concentration of peptide that leads to half the 
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maximal activation of T cells in a given population for a constant number of APC 
[158]. The peptide concentration at which T cell activation occurs is suggested to be 
inversely proportional to the affinity of the TCR. 
 
Negative selection results from high avidity interactions with self pMHC complexes 
and involves TCR mediated apoptosis [159], whereas low avidity interactions with 
self pMHC complexes promote survival of naïve immature thymocytes (positive 
selection) [159]. Alternatively the self-reactive TCR can be edited by V(D)J 
recombination to display a less reactive TCR, or TCRs can be down-regulated and 
activation inhibitory receptors can be up-regulated (such as CTLA4) in response to 
strong stimulation in the thymus [160]. 
 
Liu and colleagues examining central tolerance relevant to EAE, found that the 
administration of MBPAc1-9 in PBS to Tg3 mice, via the intraperitoneal route, resulted 
in unresponsiveness of T cells [49]. Further examination of the model showed that a 




 cells in the thymus occurred within hours of 
administration, indicating that the mechanism of tolerance is deletion. 
 
 
1.5.2. Peripheral Tolerance 
 
Central tolerance is not a perfect system however, and some self-reactive T cells can 
escape clonal elimination and therefore must be controlled via peripheral 
mechanisms in order to avoid harm. 
 
There appear to be three key principles currently suggested concerning peripheral 
tolerance to self and administered antigen; deletion, regulation and anergy-
adaptation. These may not be exclusive and it is possible that a T cell may 
experience the latter two before going on to be deleted [161]. 
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The consensus view is that peripheral tolerance is maintained by self-antigen 
presentation by steady state (the ‘absence of deliberate exposure to maturation 




Peripheral T cells can die by either extrinsic or intrinsic mechanisms. Death in the 
absence of appropriate cell survival signals is also known as death by neglect or 
activated-cell autonomous death (ACAD) [163]. Death by excessive stimulation of 
an already activated cell is termed activation – induced cell death (AICD) [164]. 
Either of these fates are determined by the signals received by the TCR and although 
both have different initiating events, both pathways converge at the caspase 
(proteolytic enzymes) level to finalise death. In an extrinsic mechanism of death pro-
apoptotic signals  are mediated through the production of a death-inducing signal 
complex (DISC) [165]. The intrinsic mechanism of death relies on the interplay 
between pro and anti-apoptotic members of the B cell lymphoma 2 (Bcl-2) family 
[166].  
 
The first observation of cell death via apoptosis was made by Ochi et al; they showed 
that a challenge with superantigen resulted in clonal expansion of relevant CD4
+
 T 
cells followed by a dramatic loss of the same cells to a level lower than in the naïve 
mouse [167]. DNA fragmentation was detected in the population of stimulated cells 
for a limited time after this activation; hence the cells were shown to have undergone 





The intrinsic apoptotic pathway may be a result of either neglect (cytokine 
deprivation) or stimuli such as UV radiation, DNA damage and endoplasmic 
reticulum stress. It is dependent on the actions of the Bcl-2 family members, BIM 
(Bcl-2-interacting mediator of cell death) and PUMA (p53-upregulated modulator of 
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apoptosis) [168]. Bcl-2 helps to regulate mitochondrial activity and once BIM and 
PUMA bind to Bcl-2 the regulation is disrupted and cytochrome c is released. This 
pathway is therefore a result of the permeabilisation of the mitochondrial membrane 
and the release of cytochrome c aids the formation of the apoptosome. Caspases 





The TCR restimulation of already activated and expanded T cells in the absence of 
signal 2 can lead to AICD [169]. Studies have used Fas (CD95) deficient mice to 
implicate the Fas pathway within AICD. Other studies have implicated TNF receptor 
1 (TNFR1) [170] and TNF related apoptosis-inducing ligand receptor (TRAILR)  




AICD was shown to be a result of the upregulation of FasL, which induces Fas-
mediated death of either the same cell on which FasL is expressed (suicide) or on a 
neighbouring cell. The pathway is dependent on the interaction between Fas and 
FasL; the upregulation of both markers on activated T cells leads to the activation of 
a CD95-DISC complex which initiates further downstream events mediating 
apoptosis of these cells [172-174]. It is the presence of IL-2 and its effects on several 
transcription factors including NF-AT and NF-κB [175] that determines Fas and 
FasL expression respectively and explains why Fas in not largely expressed on naïve 
cells. During the course of normal disease AICD appears to limit pathology by 
preventing the over-expansion of relevant T cell populations when antigen is 





As early as 1969, Sakakura and colleagues [177] showed that thymectomy of mice at 
day two of life led to autoimmune ovary destruction. Evidence has since gathered to 
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show that peripheral tolerance is aided by nTregs that have been selected for in the 
thymus. These cells have higher avidity than positively selected T cells but lower 









 Regulatory Cells make up around 10% of the normal CD4
+
 T cell population  
in mice [180]. These cells are found to co-express CD25 (IL-2 receptor α chain) 
[181] and have been shown to control the expansion of self-reactive cells. However 
the nTreg population has only recently been fully distinguished from activated CD4
+
 
T cells expressing CD25 by the expression of the X-chromosome-encoded forkhead 





 cells [184]. CD25
-
 cells found to express Foxp3 were CD45RB
lo
 and 










Tregs are able to suppress T cell proliferation in vitro 
suggesting that IL-2 is not required for suppression to occur. The existence of a 
Foxp3
+
 population of nTregs in these mice also indicated that IL-2 is not essential in 
thymic selection of nTregs however IL-2 signalling has been shown to be a 




 population of cells express the CD25 marker regardless of activation 
state alongside expression of CTLA-4,
 
glucocorticoid-induced tumour necrosis factor 
receptor family-related
 
gene (GITR) [186], and a minority express CD103 ( E 
integrin) [184]. 
 




 cell populations into athymic mice results in the 









 transfer prevents autoimmune pathology in cell dose-
dependent manner [181]. Tregs require TCR ligation by specific antigens in order to 
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exert regulatory effects; this suggests that Tregs need to be self-reactive to some 
degree to allow control of other self-reactive cells [187].  
 







 T cell repertoires was established through 
sequence analysis. The specificity of cloned Treg TCR was then analysed using 
retroviral expression in mono-specific TCRαβ transgenic recombination-activating 
gene knock-out (RAG
-/-
) T cells. This approach showed that a large proportion of 
CD25
+
 TCR were more effective in recognising constitutively presented self-
antigens, compared to the CD25
-
 repertoire [188]. 
 
nTregs are thought to mediate their effects through IL-10 and TGF-β1 production 
[98, 189]. IL-10 production is not dependent on the expression of Foxp3 or CD25. 
However chronic antigenic stimulation is known to  result in CD25
+
 cells; these TR1 
cells produce IL-10 and appear to be as efficient as nTregs in suppressing disease 
[190, 191]. Both nTregs and TR1 cells are shown to decrease IL-2 production to 
similar extents [191]. 
 
 
T Regulatory 1 (Tr1) Cells 
 
The first identification of Tr1 cells was by Groux and colleagues; these OVA-
specific transgenic cells were generated experimentally in vitro by chronic 
stimulation with IL-10 and OVA peptide [98]. These cells can be distinguished from 
Th1 and Th2 cells by their secretion of high levels of IL-10 as well as secreting low 
levels of IL-2, IL-4, IL-5, TGF-β and IFN-γ [98]; the levels of secretion of cytokines 
(except IL-10) depend on the model in which the Tr1 cells are induced. Tr1 cells 
have also been isolated from human peripheral blood. Tr1 cells express the IL-2 and 
IL-15 receptor α chains in conjunction with either the receptor β or γ chains of both 
cytokines  [192]. 
 
 34 
In an EAE model of epitope spreading, the administration of a spreading determinant 
(MBP68–86), in rats immunised with MBP87–99 and CFA activated Tr1 cells and 
potentiated their expansion in the cervical lymph nodes and spleen. The antigen 
relevant production of IL-10 from these cells was implicated in the bystander 
suppression of disease; the administration of anti-IL-10 antibodies abrogated the 
effect of Tr1 produced IL-10 [193]. 
 
 
T Helper Type 3 (Th3) Cells 
  
Oral tolerance is of importance in immunology because it is a continuous natural 
immunological event which is driven by exogenous antigen. Within EAE this was 
first shown in the Lewis rat with high doses of MBP by Bitar et al and multiple low 
doses of MBP by Higgins et al 1980s [194, 195]. Later work revealed that the 
mechanism of tolerance in high dose administration was anergy [196] whereas in low 
dose administration it was via transferable cellular suppression [197].  
 
T cell clones from orally tolerised mice have been isolated and have been defined as 
the unique set of CD4
+
 cells, Th3 [198]. These cells are MHC class II restricted and 
share the same αβ TCR as Th1 and Th2 cells [189]. They appear to require IL-4 
rather than IL-2 for growth and some clones produce low level amounts of IL-10 
and/or IL-4 but no IFN-γ or IL-2 upon TCR ligation [198].  
 
The Th3 repertoire is thought to primarily exert its effects through the production of 
TGF-β1 upon TCR ligation. They are thought to mediate TGF-β suppression through 
a cell-contact dependent mechanism relying on surface bound TGF-β [189]. Studies 
have shown TGF-β1 dependent suppression of CD8+ T cells in type 1 diabetes [199] 
and tumour environments [200] as well as suppression of CD4
+





Regulation in EAE 
 
The role of B cells in regulation was suggested by Janeway and colleagues who 
reported that µMT mice on the H-2u background failed to recover from EAE [201]. 
The same effect was seen by Fillatreau and colleagues in µMT mice on the H-2b 
background immunised with MOG35-55 [99]. Adoptive transfers of B cells from 
recovered mice into recipient naïve mice have shown protection against subsequent 
disease induction. IL-10
-/-
 mice show the same lack of disease remission as µMT 
mice [97] and on closer examination the effector or memory B cells taken from mice 
recovered from EAE have shown secretion of IL-10 when stimulated through BCR 
and CD40 [202].  
 
B cells from MS patients produce a decreased amount of IL-10 compared to non-
sufferers suggesting that these cells have a role in regulation or limitation of MS 
onset [203]. Recent observations show that B cells can also be stimulated to produce 
IL-10 through TLRs 2 and 4. The B cells however are unable to mediate suppressive 
effects on activated T cells by themselves; the B cells affect the production of IL-6, 
IL-23 and TNF-α from DC through IL-10 dependent mechanisms [204]. Despite 
these findings showing the necessity of B cells in the recovery of EAE; kinetic 
studies show that B cells do not accumulate in the CNS, in significant numbers, at 
any point during a course of the disease. 
 







 T cells only within the CNS. One in three CNS 
CD4
+
 cells were Tregs and from this population one in three could produce IL-10 
(around 10% of the total CD4
+
 CNS infiltrate). The depletion of these cells impaired 
recovery and the transfer of the same population back into sick mice ameliorated 
disease [205]. Treg depletion was also seen to exacerbate PLP139-151 induced EAE. 
The same series of experiments identified a role for TGF-β by showing that anti-
TGF-β treatment prevented recovery from disease [206]. 
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These data suggest that B cells play a role in preventing the expansion of T cells with 
pathogenic potential in the peripheral lymphoid organs but it is the Tregs that are the 
dominant force of regulation within the CNS.  
 
 
Functional Inactivation of Lymphocytes 
 
Anergy is the term coined for a situation where lymphocytes are functionally 
inactivated following an encounter with an antigen. For lymphocytes to be ‘anergic’ 
they must be hypo-responsive and also must stay alive for much longer than the 24 
hours reflective of cells in an apoptotic state [207]. Anergy is currently categorised 
into two types, clonal anergy and adaptive tolerance. Schwartz suggests that clonal 
anergy is a phenomenon of cell cycle arrest in activated T cells whereas adaptive 
tolerance (or adaptation) is a result of persistent stimulation of naïve T cells [207]. 
Lechler et al showed that the conditions that led to the non-responsiveness of 
activated T cells, the ligation of the TCR without full co-stimulation, failed to 
anergise naïve T cells [208]. 
 
A likely cause for clonal anergy appears to be the failure of a CD28-B7 interaction 
whilst the TCR is being ligated leading to an unresponsive cell. CD28 signalling 
down-regulates the cell cycle inhibitor p27
kip1
. In the absence of CD28 signalling, 
p27
kip1
 is able to bind to and block the actions of cyclin E-Cdk2 in late G1. E-Cdk2 is 
required to phosphorylate anti-proliferative transcription factors Smad 2 and Smad 3 
and hence allows entry into S phase and induces production of IL-2; IL-2 itself then 
acts to down-regulate p27
kip1
 [209, 210]. CTLA-4 may act to inhibit CD28 signalling 
and hence induce anergy [208]. 
 
The presence of Rapamycin can also induce anergy, even with CD28 ligation and the 
production of IL-2 by activated cells. Rapamycin exerts its effects by inhibiting the 
activation of mTOR, a protein kinase required for cell division [207, 209]. 
 
Recent studies have shown a defect in LAT phosphorylation and palmitoylation in 
anergic cells. As LAT is the primary site where key molecules such as GBR2, SLP-
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76 and PLCγ1 come together this has obvious effects on the ability of a TCR signal 
to be propagated [211].  
 
The uncoupling of Ras from the TCR in anergic cells has also been cited as a key 
event in maintenance of anergy. Ras binds GTP even in anergic cells to form Ras-
GTP, however the problem appears to be the constitutive expression of GTP-
activating protein (GAP) which converts Ras-GTP into the inactive form Ras-GDP 
[207]. Ras-GTP activates Raf-1 however this can be prevented by the actions of 
Rap1-GTP. The action of diacylglycerol (DAG) to lead both Ras-GTP and Raf to the 
immunological synapse appears key to the MAP kinase and ERK signalling 
pathways respectively. The excessive production of DAG kinase in anergic cells 
leads to loss of DAG and hence impairs both signalling pathways; this in turn 
dampens transactivation of the AP-1 transcription factor which mediates the 
production of IL-2 [212]. Importantly it has been also noted that the constitutive 
production of Ras in anergic Th1 clone restores IL-2 production and MAPK activity 
[213]. 
 
The ubiquitylation pathway is used to target a protein for destruction by the 26S 
proteosome. It consists of a core molecule, Ubiquitin, enzymes involved in ubiquitin 
attachment (ubiquitin ligases E1, E2 and E3), deubiquitylating enzymes and 
ubiquitin-binding proteins. The E3 ubiquitin ligases that have been identified in 
relation to anergic T cells include CBL-B [214], GRAIL (gene related to anergy in 
lymphocytes) [215] and ITCH (itchy homologue E3 ubiquitin protein ligase). 
 
CBL-B prevents the association of CD28 and phosphoinositide 3-kinase by 
polyubiquitylating the p85 subunit of the latter. This inhibits the signal 2 cascade. 
CBL-B and GRAIL inhibit actin reorganisation which is required to allow the 
formation of the immune synapse. GRAIL mediates this by polyubiquitylating and 
stabilising the RHO-guanine-dissociation inhibitor. ITCH monoubiquitylates PLC-γ1 
and PKC−θ and therefore can have an impact on the calcium signalling pathway , the 
DAG pathway and the PKC pathway which modulate NF-AT, AP-1 and NF-κB 




Adaptive tolerance is essentially unresponsiveness to persistent antigen stimulation 
with the key being that the cell can return to a functional phenotype once the 
stimulus is removed; that is to say, the state is reversible. This system is beneficial in 
limiting T cell mediated damage to host after a pathogen is cleared from the system. 
Adaptive tolerance can be explained in part by the tuneable activation threshold 
(TAT) model postulated by Grossman and Paul [217]. This model explains the 
modulation of T cells in response to antigenic stimulation; theorising that T cells 
maintain tolerance to self-MHC-peptide complexes by tuning their TCR signalling to 
match the background level of stimulus. A rapid change in the level of stimulus will 
elicit a response from the T cells however if this new stimulus is constant or 
recurrent, then the T cell will adapt accordingly by readjusting its activation 
threshold [218, 219] to once again being tolerant to this new stimulus. Hence the T 
cell remains functionally unresponsive to stimuli of strengths equal to or below that 
of the initial persistent stimulus [161]. 
 
Schwartz and colleagues created a model of adaptive tolerance where they were able 
to exclude the problems of studying relevant T cell repertoires in a heterogeneous 
environment. RAG
-/-
 TCR transgenic CD4
+
 mice specific for pigeon cytochrome C 
(PCC) were crossed with a second transgenic mouse which expressed PCC under the 
control of an MHC class I promoter and an Ig enhancer. This second mouse had 
already been crossed with a CD3e
-/-
 mouse and therefore had no T cells. The final 
mouse had a large monospecific adapted T cell population with minimum deletion 
due to the low expression of antigen. If cells from this mouse were transferred into a 
host not presenting PCC then they regained responsiveness however if transferred 
into a host with PCC the cells initially regained responsiveness but then settled into a 
deeper state of adaptation than before. The intrinsic adaptive tolerance of the CD4
+
 
cells in this mouse could be induced to different levels. These observations showed 
the reversibility of the adaptive tolerogenic state [220].  
 
Various differences exist between anergic and adapted cells. The main difference 
appears to be at the level of T cell signalling impairment. As discussed earlier, the 
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Ras / MAP kinase pathway is inhibited in anergy whereas Zap-70 appears inhibited 
in adaptive tolerance, leading to disruption of the calcium and NF-AT pathways 
[221]. Furthermore in adapted cells the blocked proliferation cannot be reversed by 
adding IL-2. Clonally anergic cells remain inactive for long periods of time after the 
antigen and APC are removed whereas adapted cells appear to regain responsiveness 
relatively quickly [207]. 
 
As discussed previously, the number of potential antigens to recognise far outweighs 
the potential number of T cells that are available to the immune system. With that in 
mind although the autoaggressive potential of T cells needs to be controlled, death 
may not be the perfect answer because some of the T cells that die may be required 
to detect non-self antigens. Adaptation appears to be the perfect solution; the 
dynamics of T cell adaptation suggests that auto-reactive T cells can be maintained in 
the peripheral T cell repertoire with the potential to react against foreign invaders 
which stimulate them greater than cognate antigen. Hence the immune system can 
maintain a more diverse T cell repertoire. 
 
 
The Role of CD5 
 
Cells seem to be adapted in part through the actions of a monomeric cell surface 
glycoprotein, CD5, which appears to negatively regulate TCR signalling. CD5 is 
constitutively expressed on T cells, B cells and thymocytes and is known to be 
associated with the TCR / CD3 complex at the T cell / APC interface. Its recruitment 
appears to be at a similar rate to CD3; its role however does not appear to be linked 
to the formation or stability of the immunological synapse. Data comparing CD5 
high, low or negative cells indicates that levels of CD5 correlate with an effect on the 
antigen induced tyrosine phosphorylation in T cells affecting the proliferative 
potential of these cells [222]. 
 
After the TCR is engaged, CD5 becomes tyrosine phosphorylated and forms a 
complex with molecules such as CD4 and Zap70 [223, 224]. Reduced CD5 levels are 
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shown to correlate with increased Ca
2+
 responses to TCR engagement [76, 225]. The 
exact mechanism by which CD5 affects signalling and whether it acts alone as a 
negative regulator of TCR is unclear as is the question of which other factors are 
involved in desensitising T cells. 
 
Ryan et al suggested that T cells can avoid Fas-mediated AICD because of a 
functional desensitisation that correlates with enhanced CD5 expression [174]. This 
was also implicated in lung carcinoma studies; incubation of T cells with an anti-
CD5 antibody resulted in a 4-fold increase in surface expression of FasL without 
showing increase in FasL mRNA levels. This would indicate that CD5 was 
preventing the delivery of FasL to the cell surface by manipulating TCR signalling. 
The level of control at which CD5 can manipulate AICD may be through Caspase-8, 
a key molecule in the in the Fas-associated death domain [226].  
 
This supports data mentioned above suggesting that CD5 was manipulating Zap-70; 
it has been shown in separate studies using NF-ATc2 and c3 deficient mice that there 
is a loss of FasL expression and impaired AICD hence the manipulation of Zap-70 
















1.6. Breaking down tolerance in autoimmune disease 
1.6.1. Molecular Mimicry 
 
A single T cell has the ability to respond to both infectious agents and self tissue 
because of the cross-reactive nature of the TCR. The molecular mimicry theory, 
within autoimmune disease, suggests that an immune response initially directed at a 
non-self antigen by a T cell can spread to a self antigen because of the cross-
reactivity of the TCR. Initial experiments compared hepatitis B with MBP and data 
suggested that foreign and self antigens had to share sequence stretches of at least 6 
amino acids in order to initiate expansion of cells relevant to the other [228, 229].  
 
Using a model of insulin-dependent diabetes mellitus (IDDM), Oldstone and 
colleagues later showed molecular mimicry at work; either the lymphocytic 
choriomeningitis virus (LCMV) glycoprotein (GP) or the LCMV nucleoprotein (NP) 
were transgenically expressed in pancreatic beta cells in mice. The data showed that 
the low expression of these viral gene products rarely produced a case of IDDM, 
however if mice were subsequently challenged with LCMV then an immunological 
attack on the pancreas results and several aspects of IDDM were observed. Although 
initial work was carried out with virions, this is not a limit to the potential of 
molecular mimicry [230]. 
 
Ohashi et al combined these findings with mice bearing transgenic TCR for the 
LCMV GP. This allowed the tracking and evaluation of a defined repertoire of 
antigen-relevant cells in H-2
Db
 transgenic mice. Results showed that tolerance in this 
model was not a result of clonal deletion, clonal anergy nor a modulation in cell 
surface markers and yet the cells showed a sustained period where they remained 
unresponsiveness [231].  
 
Sequence similarities between MBP and viral peptides have been indicated in 
database searches and in vitro testing of MBP relevant human T cell clones has 
shown that some of these clones showed reactivity to some of the viral peptides 
[232]. Greater clarification of the binding of antigen to the TCR and the MHC class 
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II molecule involved led to the discovery that cross-reactivity was determined by key 
residues within the antigen sequences that were embedded in each receptor [232, 
233]. The identification of these contact motifs indicated a more frequent cross-
reactivity in T cell recognition than previously thought. 
 
Using the EAE model, Fujinama and Oldstone showed that immunisation of rabbits 
with the hepatitis B viral polymerase induced CNS inflammation but not active 
disease [229]. Similarly, sequences homologous to the myelin PLP found in murine 
hepatitis virus and haemophilus influenzae type B could stimulate PLP139-151 relevant 
cells but could not actively induce disease; although they did enhance disease when 
PLP was subsequently administered [54]. 
 
More recent work showed that a MBP87-99 relevant TCR could bind a sequence that 
differed from the MBP87-99 sequence in all 13 amino acid positions. This would 
negate the theory that shared amino acid anchor residues between sequences are 
required and indicate that each amino acid within a sequence contributes to the 
overall affinity of the MHC-peptide complex to the TCR [234]. The TCR would 
seem far more promiscuous than initially thought [235]. 
 
1.6.2. Escape from Central Tolerance In EAE 
 
Central tolerance is not a perfect system and some EAE models can help to explain 
how certain auto-aggressive T cells end up within the peripheral repertoire.  
 
The PLP139-151 epitope is the immunodominant epitope of PLP within H-2
s
 mice and 
yet the frequency of PLP139-151 reactive CD4
+
 cells within the SJL strain is as high as 
1/20,000 CD4
+
 cells. The gene which encodes PLP is alternatively spliced to produce 
the DM20 isoform which lacks the 116-150 sequence and therefore also the PLP139-
151 epitope. This isoform is preferentially presented in thymic selection, despite both 
DM20 and PLP being presented within the CNS, and therefore allows the escape of 
relevant cells from negative selection into the periphery because the PLP139-151 
epitope is either absent or present in very low levels [42] [236].  
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The immunodominant epitope in H-2
U 
mice, MBPAc1-9, is notable for its 
immeasurable binding affinity to the A
u
 MHC class II molecule. It is the lysine at 
position 4 of the sequence that is to blame for the poor MHC binding as it interacts 
unfavourably with the hydrophobic pocket in the I-A
u
 binding groove [237] [238]. 
An avidity based model of selection in the thymus suggests that Ac1-9 relevant T 
cells may be allowed to survive due to poor interaction with the presented antigen 
[49]. This can be used to explain the escape of a high frequency of MBPAc1-9 relevant 
T cells bearing high affinity TCR into the peripheral T cell repertoire. 
 
1.7. Peptide Induced Therapeutic Tolerance 
 
Peptide alone cannot induce EAE, hence the use of adjuvant to provide the ‘danger’ 
signal which helps to induce disease. The presentation of antigenic peptide in the 
absence of co-stimulatory molecules has long been known to cause T cell tolerance 
through anergy [239] due to the absence of Signal 2. If harnessed for therapy, peptide 
induced tolerance may be preferential to other forms of therapy because it allows for 
the manipulation of only the disease relevant cells and with the various routes in 
which peptide can be administered the level of control exerted upon the immune 
response can be more closely monitored and adjusted. 
 
There are four different protocols currently used to facilitate the induction of peptide 
mediated therapeutic tolerance; soluble-peptide induced tolerance, mucosal (nasal or 
oral) induced tolerance, peptide coupled cell induced tolerance and altered-peptide 








Soluble Peptide Induced Tolerance 
 
Soluble-peptide induced tolerance has previously been successful in the prevention 
of disease in models of type 1 diabetes [240] and several groups have shown EAE 
induction in mice is suppressed when soluble encephalitogenic MBP epitopes are 
administered intraperitoneally and intravenously (i.v.) without adjuvant [241, 242]. 
Low doses of peptide are shown to result in an immune response whereas a high dose 
results in tolerance – deletion [243] and anergy [244]. 
 
Hilliard [245] and others [246] have showed that the i.v. administration of peptide 
after onset of disease leads to clonal deletion of cells via apoptosis whereas 
administration of peptide just prior to or just after immunisation results in antigen-
specific regulation leading to tolerance. This group has also shown that the tolerance 
induced by i.v. administration of peptide results in the suppression of IL-12 [246].  
 
High-dose peptide treatment in mice with an established course of EAE has however 
been known to induce a fatal anaphylactic response in some murine strains [247] and 
i.v. MOG administration in primates has been shown to intensify disease [248]. 
 
Mucosal and Peptide-Coupled Cell Induced Tolerance 
 
Mucosally induced tolerance is based on the introduction of large numbers of foreign 
antigen into the body, via food, and the ability of the immune system not to react 
against them, except in the case of food allergies. Mucosal tolerance is advantageous 
because of the ease of administration and a decreased risk of toxicity compared to 
injection of antigen. 
 
Mice with expanded DC populations, after a single feeding with MBP, were shown 
to be tolerant to EAE induction potentially due to quiescent DC; DC that had been 
stimulated with LPS did not confer tolerance. Tolerance inducing DC also appeared 
to have up-regulate the production of IL-4, IL-5 and IL-10 thus indicating a 
bystander regulation mechanism.  
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High dose oral antigen has been shown to induce anergy or deletion of antigen 
relevant cells [194, 241]. Antigen is absorbed through M cells in the Peyer’s patch 
and is delivered via the bloodstream to the spleen or lymph nodes where it is detected 
and taken up by DC. The DC can then process and present the antigen to circulating 
T cells [249]. DC induce tolerance in T cells after the induction of signal 1; instead 
of T cells slowing down and allowing longer contacts through DC signalling, 
resulting in priming, the DC appear to no longer provide these signals and the T cells 
remain dynamic leading to tolerance [250]. Low dose oral antigen tolerance is based 
on the induction of Th3 cells [198] or by the induction of bystander suppression. 
 
Within EAE, attempts to prevent the induction of disease with prior nasal or oral 
administration has been successful [251, 252] however treatment of pre-established 
disease has only been successful using a combination of antigen and soluble IL-10  
[253]. 
 
If peptides given orally can induce tolerance then the implications for autoimmune 
disease  are clear. Unfortunately clinical trials have thus far been unsuccessful [18]. 
 
Peptide coupled cell induced tolerance relies on the use of ethylene carbodiimide 
fixed splenocytes coupled to the relevant antigen. The intravenous introduction of 
cells coupled with PLP antigens has been reported to prevent the induction of EAE 
[254]. There are two mechanisms that are suggested to explain the actions of these 
peptide coupled cells; sub-optimal activation of T cells in the absence of signal 2 or 
the induction of apoptosis of the coupled cells and the re-presentation of their 
peptides in a non-inflammatory manner by macrophage.  
 
Altered Peptide Ligand Induced Tolerance 
 
Evavold et al originally used the phrase ‘altered peptide ligands’ to describe peptides 
that had individual amino acid substitutions to define residues important in 
interacting with TCR or MHC molecules [255]. Today the term incorporates peptide 
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sequences with multiple amino acid substitutions. APL are able to be used to 
manipulate the TCR signalling cascade because they can compete for the same TCR 
binding sites as wild-type antigens. Single or double amino acid substitutions within 
the relevant sequences allow APL to retain a certain degree of agonistic potential. 
Sub agonist APL are still able to activate T cells but to a lesser degree than the wild-
type peptide, whereas superagonist APL activate T cells to a greater extent than the 
wild-type. 
 
Initially, experiments by Wraith and colleagues used these APL to establish the key 
residues for the binding of MBPAc1-9 to both the MHC Class II molecule and the 
TCR. Substitutions in the wild type (4Lys) sequence showed that residues 3 and 6 
were critical to TCR binding whereas 4 and 5 were critical to MHC binding [256, 
257]. 
                                
In later EAE experiments, Smilek and Wraith [258] used a variation of the MBP 
Ac1-9 epitope to modulate disease course - 4Ala (substitution at position 4, replacing 
the Lysine with Alanine). Whereas 4Lys immunisation gave a standard course of 
disease, co-immunisation with 4Ala prevented disease. This data suggested that, 
although the T cells may not have reacted to the APL, they were certainly aware of 
its presence and had changed their behaviour accordingly.  
 
A tyrosine substitution allowed further manipulation of disease course through 
mucosal tolerance. Intranasal administration of the 4Tyr APL was shown to suppress 
disease induced with the 4Lys peptide [259]. This tolerance was shown to be dose 
dependent; high doses resulted in deletion of cells or anergy, whereas low doses 
induced regulatory T cells which down-regulated the disease-relevant cells. In this 
series of experiments, 3 key facets of the APL were elucidated: antigenicity in vitro 
correlates to tolerogenicity in vivo; tolerogenicity does not correlate to 




Work on T cell lines (TCL), generated against APL, using B10.PL mice showed that 
cells responded to the priming APL at nM concentrations; however as the 
superagonist properties of the APL increase there is an associated loss in their 
capacity to react against the 4Lys peptide. This implicated reduced sensitivity of 
4Tyr stimulated cells as the cause of an impaired response to 4Lys peptide in the 
CNS and hence explains the inability of 4Tyr to induce disease [260]. Later work 
provides strong evidence to suggest that AICD is also responsible for 4Tyr’s inability 
to cause disease [159] and that this is dependent on FAS and FASL expressed on the 
T cells themselves [174]. 
 
In the same disease model, using the Tg4 transgenic mouse and a series of MBPAc1-9 
based APL, Ryan et al showed that superagonist APL stimulation in vitro limited the 
pathogenic potential of auto-aggressive cells to the wild-type antigen. Two 
mechanisms were implicated in this tolerance, deletion of some members of the 
repertoire through Fas mediated apoptosis and adaptation of others [174, 261]. 
However in vivo immunisation with some of these super-agonist APL led to the 
induction of disease [50].  
 
Steinman and colleagues have developed an APL system based on the 87-99 epitope 
of MBP and have shown that TNF-α and IFN-γ production from lymph node cells 
can be reduced when MBP87-99 is administered alongside an antagonist APL 
compared to MBP87-99 immunisation alone [262]. 
 
In EAE experiments with PLP139-151 analogues, results in vitro suggested the APL 
acted as antagonists and in vivo suppressed EAE induced with a variety of PLP, MBP 
and MOG epitopes [263]. These APL were also found to deviate the immune 
response and T cell clones raised to them were found to produce IL-4, IL-10 and 
TGF-β [264]. PLP itself has been shown to suppress proliferation responses to MBP 
peptides when administered intranasally. PLP has also been shown to reduce relapse 




1.8. Epitope Spreading  
 
Epitope Spreading is the diversification of the immune response from an initial 
epitope to a secondary epitope either on the same protein or on a separate protein; it 
has been suggested that epitope spreading may be responsible for the relapses in 
relapsing-remitting course of MS.  
 
The epitope spreading paradigm was first observed by Lehmann et al, in an EAE 
model, when disease was induced in the B10.PL x SJL model using MBPAc1-9 [265] 
and the immune response was seen to change its focus to other epitopes on MBP 
after an initial Ac1-9 directed response. This observation is now described as 
intramolecular epitope spreading. Intermolecular epitope spreading is when the 
immune response spreads from an epitope on one molecule to an epitope on another 
molecule [266].  
 
As Figure 1.3 shows both these types of spreading are seen in SJL mice immunised 
with PLP139-151, which results in a relapsing–remitting form of EAE. Using T cell 
proliferation assays it has been shown that, just before and during the first relapse, 
PLP178-191 reactivity occurs (intramolecular epitope spreading) and that MBP84-104 
responses are seen in the second relapses (intermolecular epitope spreading) [267]. It 
is suggested that the myelin destruction mediated in the first episode of EAE reveals 
the PLP178-191 cryptic epitope leading to a PLP178-191 directed immune response; the 
first relapse causes further damage to the myelin revealing the MBP84-104 cryptic 
epitope (Figure 1.3). 
 
Hence tissue damage caused in the CNS during an initial phase of EAE may prime a 
hierarchal cascade of autoaggressive T cells by revealing cryptic epitopes against 
which several phases of disease are subsequently directed. In this scenario, if epitope 
spreading is responsible for the relapses in MS then the changes in specificities of the 
immune response over a period of time could pose problems for single antigen-based 
immunotherapy. Future therapeutic measures would need the ability to modulate 
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pathogenic responses to several antigens as immune responses to individual antigens 
fluctuate.  
 
A flipside to epitope spreading is the phenomenon of bystander suppression; the 
concept that regulatory cells induced by one antigen can suppress immune responses 
stimulated by another antigen. This was first described in an investigation of 
regulatory cells that were induced by oral administration of low doses of MBP 







































































1.9. Aims of Project 
 
This project had three aims: 
 
 
1. To develop novel TCR transgenic based models to investigate epitope 
spreading and adaptive tolerance.  
 
2. To determine the contribution of epitope spreading in PLP139-151 induced EAE 
by tracking and characterising disease relevant pathogenic and regulatory T 
cells and to assess their contribution on the course of disease 
 
3. To investigate the tuning of the immune response at both a T cell population 
and individual level in MBPAc1-9 induced disease. To assess the impact of 
adaptation on the autoreactive T cell repertoire in terms of behaviour and 
phenotype. We also wished to determine the mechanisms involved in 
































































All mice were bred and maintained, under specific pathogen free conditions, at The 




) and B10.PL (H-2
u
) mice were used extensively to produce the 
C57BL/6 x B10.PL F1 (H-2
u,b
) mouse. SJL (H-2s) mice were used to produce the 
B10.PL x SJL F1 mouse. Transgenic strains utilised included the 2D2 [43] mouse, on 





 congenic mice were also used. All mice were sex-matched 




MOG35-55 (MEVGWYRSPFSRVVHLYRNK), MBPAc1-9  4Lys (ASQKRPSQR), 
MBPAc1-9 4Tyr (ASQYRPSQR) and PLP139-151 (HCLGKWLGHPDKF) were 
synthesised by the Advanced Biotechnology Centre, Imperial College, London using 




Complete and incomplete Freud’s adjuvants (CFA and IFA respectively) were 
obtained from Sigma, Poole, GB. CpG oligonucleotide was obtained from MWG 




2.4. General Reagents 
 
2.4.1.1. Tissue wash buffer:  
RPMI 1640 medium containing 25mM HEPES buffer, 2mM L-Glutamine, 100U/ml 
Penicillin, 100µg/ml streptomycin and 5x10-5 2-mercaptoethanol (all from Gibco, 
Life Technologies, Paisley, UK hereafter referred to as Gibco). 2-mercaptoethanol 
acts as a reducing agent and improves conditions for cell survival. 
 
2.4.1.2. RPMI-5 tissue culture medium: 
Tissue wash buffer with the addition of 5% foetal calf serum (FCS; Sigma; heat-
inactivated for 30 minutes at 56°C to denature complement). 
 
2.4.1.3. MACS buffer:  
Hanks Balanced Salt Solution with 2% heat-inactivated FCS, 100U/ml Penicillin and 
100µg/ml streptomycin (Gibco). 
 
2.4.1.4. FACS buffer: 
PBS (sterile; magnesium- and calcium-free; Gibco) supplemented with 2% FCS. 
 
2.4.1.5. Pertussis Toxin (PTx): 
PTx was obtained from the Health Protection Agency, Dorset, UK and diluted in 
PBS. 
2.4.1.6. Bicarbonate Buffer (10x) 
Na2CO3 (6.36g) and NaHCO3 (11.72g) were dissolved in 400ml of double-distilled 
H2O. The solution was adjusted to pH9.6. 
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2.4.1.7. Phosphate-citrate Buffer (PCB) 
Na2HPO4 (27.5ml) and 0.1M anhydrous citric acid (24.3ml) were added together and 
made up to 100ml using double-distilled H2O, with the pH adjusted to 5. 
 
2.5. Preparation and Purification of Cell Populations 
All cell isolation techniques were based on previously optimised systems from within 
the Anderton group. 
2.5.1.1. Isolation of mononuclear cells from CNS tissues 
 
Mice were sacrificed by CO2 asphyxiation, the aorta was then cut and mice were then 
perfused with 25ml of PBS through the left ventricle of the heart. Brains were 
removed by dissection after decapitation. Spinal cords were removed by intrathecal 
hydrostatic pressure using PBS. The tissues were broken down by mechanical 
disaggregation and digested, for 30 minutes at 37°C, in wash buffer containing 
2.5mg/ml collagenase (Worthington Biochemicals, NJ) and 1mg/ml 
deoxyribonuclease (Sigma). A single cell suspension was then obtained by further 
mechanical disaggregation; cells were then washed with RPMI-5. 
 
Cells were then suspended in 30% Percoll (Gibco – made up with RPMI-5) overlaid 
on 70% Percoll. This allowed the separation of mononuclear cells from the rest of the 
tissue components, mainly fats, at the gradient interface. Cells were subsequently 





 Cell Purification 
 
Peripheral lymph nodes and spleens were taken from donor mice and single cell 
suspensions were obtained by mechanical disaggregation. Red blood cells (RBC) 
were removed after incubation with RBC lysis buffer (Sigma). Cells were then 
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resuspended in MACS buffer and counted. Cells were incubated with 45µl of MACS 
buffer and 5µl of MACS anti-CD4+ beads per 107 cells for 15 minutes. Cells were 
then washed in MACS buffer and passed through MS or LS columns according to 
the manufacturer’s instructions (Miltenyi Biotec). Cells retained in the magnetic 
column (CD4
+
 fraction) were collected. Samples were stained with anti-CD4-APC 
and the purity was analysed. Purity obtained was consistently above 90%. Cells were 
resuspended in PBS and filtered to remove clumps. They were injected intravenously 
into pre-heated tail veins at a final volume of 200µl per mouse. 
 
 
2.6. Generation of short-term T cell cultures 
 
Short term cultures, for the investigation of adaptive tolerance, used Tg4 T cells and 
culture conditions were based on passive transfer culture conditions established by 
O’Connor et al [268]. Spleen and lymph nodes from naïve Tg4 mice were 
mechanically disaggregated to produce a single cell suspension. Cells were plated at 
5x10
6 
cells per well in RPMI-5 (24-well plate; 1.5ml per well); peptide was added to 
these cultures to stimulate the cells (10µg/ml of 4Lys, 1.0µg/ml 4Tyr, 0.1 µg/ml 
4Tyr and 0.01 µg/ml 4Tyr). Cultures were maintained using a seven day re-
stimulation cycle. In the first round of stimulation the Tg4 APC recovered with the T 
cells were used for stimulation and total cells were plated at 5x10
6
 cells per well in a 
24-well plate. In secondary and tertiary rounds of stimulation γ-irradiated (using a 
caesium isotope, 
127
Cs) B10.PL splenocytes were used as APC; 1x10
6
 T cells were 
plated with 3x10
6
 irradiated splenocytes. Cells were stimulated with peptide for 
approximately 3 days. T cell blasts were then isolated using a Nycoprep 1.077 animal 
density gradient (Nycomed Pharma, Oslo, Norway - no longer sold) and resuspended 
in RPMI-5 supplemented with 2% rat concanavalin A supernatant. Cells were rested 
in this medium for four days before being re-stimulated as above. Flow cytometric 




2.7. Induction of EAE 
2.7.1.1. Single immunisation EAE induction  
 
MOG35-55 or 4Lys were administered, sub-cutaneously, in both hind legs with a total 
of 100µg of peptide, per mouse, emulsified in CFA. 200ng of PTx in 0.5ml PBS was 
given intraperitoneally on the same day and again two days later. 
 
The PLP139-151 peptide was administered into B10.PLxSJL mice sub-cutaneously at 
200µg of peptide, per mouse, emulsified in CFA. 200ng of PTx in 0.5ml PBS was 
given intraperitoneally on the same day and again two days later. 
 
2.7.1.2. Dual immunisation EAE induction  
 
4Lys or 4Tyr (100µg) were administered, sub-cutaneously, in the left leg with 50µg 
of peptide, per mouse, emulsified in 50µl IFA supplemented with 60µg CpG. After 
28 days, EAE was induced using either 100µg 4Lys or 100µg 4Tyr with CFA 
administered into the right leg. PTx (200ng in 0.5ml PBS) was given 
intraperitoneally on the same day and again two days later. 
 
2.7.1.3. Passive transfer of EAE 
 
Passive transfer cell culture conditions and timings were based on previous work in 
the MOG35-55 / C57BL/6 model of EAE by O’Connor et al [268]. In C57Bl/6 x 
B10.PL mice, passive EAE was induced by immunising donor C57BL/6 x B10.PL 
mice with 100µg of MOG35-55, per mouse, emulsified in CFA. Inguinal and 
paraaortic lymph nodes were removed from these animals ten days later and a single 
cell suspension was produced as described above. Cells were plated out at 5x10
6
 
cells per well in a 24-well plate, with RPMI-5 containing 10µg/ml of MOG35-55, 
0.5ng/ml IL-2,  25ng/ml IL-12 and 25ng/ml IL-18 (total well volume of 2ml). After 
48 hours, cells were re-stimulated with 2.5ng/ml IL-2 in fresh RPMI-5 added in a 1:1 
ratio with the culture volume. Twenty-four hours later T cell blasts were isolated 
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using Nycoprep 1.077 and then washed with RPMI-5. Cells were filtered to remove 
clumps and resuspended in PBS at 20x10
6
/ml and then injected intravenously into 
pre-heated tail veins at a final volume of 200µl (4x106 T cell blasts per mouse). 
Purity of cells was not assessed prior to transfer. 
 
Tg4 cells were treated in the same manner as this, except mice were not immunised 
and both splenocytes and lymph nodes were taken for culture. Varying doses of 
either 4Lys or 4Tyr were used for stimulation with polarising cytokines as above. In 
experiments where two rounds of in vitro stimulation were required, cells were rested 
in RPMI-5 supplemented with 2% rat concanavalin A supernatant for four days after 
primary stimulation. They were then stimulated again for three days, in the absence 
of polarising cytokines, with irradiated B10.PL splenocytes. Cells were then 
resuspended in PBS at 25x10
6
/ml and injected intravenously into pre-heated tail 
veins at a final volume of 200µl (5x106 T cell blasts per mouse). Mice were given 
PTx (200ng in 0.5ml PBS) intraperitoneally on the same day and again two days 
later.  
 
2.7.1.4. Assessment of EAE 
 
Clinical signs of EAE were assessed daily using a standardised scoring index: 0, no 
signs; 1, flaccid tail; 2, impaired gait and/or impaired righting reflex; 3, partial hind 
leg paralysis; 4, total hind leg paralysis; 5, hind and fore leg paralysis; 6, moribund 
or dead. Mice were weighed prior to immunisation and during disease course; mice 
showing a 20% reduction in weight or a score of 5 two days in a row were culled. 
Differences in total disease burden between groups were determined using the Mann-







2.8. Induction of tolerance with soluble peptides 
 
Mice received a single intravenous dose of 200µg of either 4Tyr or PLP139-151 in 
200µl of PBS seven days prior to immunisation with PLP139-151 or 4Lys, respectively, 
with CFA. This protocol was based on previous work by Anderton et al [259]. 
 
2.9. Flow Cytometric Analysis 
 
Single cell suspensions were prepared as described above and were resuspended in 
FACS buffer. Antibodies used for staining were prepared in FACS buffer (clones and 
concentrations as described in Table 2.1). Cells were incubated with antibody for 15-
20 minutes at 4°C before being resuspended in FACS buffer and passed through a 
Becton Dickinson FACSCalibur or LSR II (BD, Franklin Lakes, NJ, USA). Data 
obtained was analysed using the FlowJo programme (Treestar, USA). 
 
2.9.1.1. Intracellular staining 
 
For analysis of antigen specific cytokine production, cells were incubated overnight 
at 6x10
6
 cells per well, in a 24 well plate with 10µg/ml of the relevant peptide. Then 
they were incubated with 1µl/ml of golgistop (BD Pharmingen, La Jolla, USA) for 4 
hours at 37°C. Cells were then stained for surface molecules for 30 minutes at 4°C 
before being treated with a cytofix / cytoperm kit (BD Biosciences) as per 
manufacturer’s instructions. Cells were then stained for cytokine production for 30 
minutes at 4°C before being processed through the LSR II. 
 
Cells analysed for Foxp3 were treated in a similar fashion. The cytofix / 
permeabilisation kit in this case was from ebiosciences. Again cells were treated as 










CD4 RM4.5 FITC/APC/PCP 1/400 
CD5 53-7.3 PE 1/200 
CD8 53-6.7 PE 1/200 
CD25 PC61 PE/APC 1/200 
CD44 IM7 PE 1/200 
CD69 H1.2F3 Biotin 1/200 
CD45.1 A20 FITC/PE 1/200 
CD90.1 HIS51 FITC/APC 1/200 
TCR-β* H57-597 APC 1/200 
Foxp3* FJK-16s FITC/APC 1/200 
IL-2 JES6-5H4 PE 1/200 
IFN-γ XMG1.2 FITC 1/200 
Fc Receptors 2.4G2 unconjugated 1/50 
* From ebioscience. All other antibodies from BD Pharmingen. 
 
2.10. In vitro assessment of T cell function  
2.10.1.1. Recall response proliferation assays 
 
Single cell suspensions were made from lymph nodes and splenocytes. Cells were 
cultured, in triplicate, using 96-well flat bottomed plates (at 6x10
6 
cells/ml per well) 
against varying doses of peptide. After 48 hours, 0.5µCi/well of tritiated thymidine 
(
3
H-dThd, Amersham) was added to the cultures. After an overnight incubation the 
cultures were harvested and the thymidine incorporation was measured using a liquid 






2.10.1.2. Cytokine production ELISA 
 
Lymph node cells and splenocytes were mechanically disaggregated to produce 
single cell suspensions which were then cultured, in 96-well flat bottomed plates, 
with varying doses of peptide as indicated on each graph. Plates were incubated at 
37°C for 48 hours before analysis. 
 
Anti-IL-2 or anti-IFN-γ capture antibodies (clones JES6-1A12 and R4-6A2 
respectively, from BD Pharmingen) were diluted to 2µg/ml and 1µg/ml respectively 
in bicarbonate buffer and were used to coat 96-well MaxiSorb microtiter plates 
(Nunc International, Roskilde, Denmark), at 50µl per well. Plates were incubated at 
4°C overnight. After being washed twice in PBS/0.1%Tween (20) the plates were 
blocked with PBS/1%BSA (200µl per well) for 1 hour at 37°C. The plates were then 
washed again, twice with PBS/0.1%Tween (20) and twice with PBS alone. IL-2 and 
IFN-γ cytokine standards were then added in duplicates (100µl per well), at top 
concentrations of 1000pg/ml and 100ng/ml respectively, in two-fold dilutions to 
produce a 10-point standard curve. Duplicate samples of culture supernatants (100µl 
per well) were added to wells in the MaxiSorb plate and 4 blank wells with 100µl 
PBS/1%BSA were also prepared. 
 
Plates were then incubated at room temperature for 2 hours before washing four 
times with PBS/0.1%Tween (20). A secondary, biotinylated anti-cytokine detecting, 
antibody (anti-IL-2-capture, clone JES6-5H4 and anti-IFN-γ-capture, XMG1.2; BD 
Pharmingen) diluted in PBS/1%BSA was added at this stage (100µl per well, at a 
final concentration of 0.5µg/ml) and the plates were incubated at room temperature 
for 1 hour. This was followed by 6 washes with PBS/1%BSA prior to incubation 
with 100µl per well of ExtrAvidin peroxidase (made up to final concentration > 
2µg/ml in PBS/1%BSA; Sigma) at room temperature for 30 minutes. Plates were 
again washed 6 times with PBS/1%BSA. Tetramethylbenzidine (TMB; Sigma) 
solution (prepared by adding 100µl of TMB in DMSO to 9.9ml of PCB and 3µl of 
hydrogen peroxide) was added to the plates (100µl per well) and was followed by 
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100ml per well of 2M sulphuric acid to stop the reaction. Absorbance values were 
read at 450nm using a Multiskan plate reader (Labsystems, Basingstoke, UK). 
 
2.11. Statistics  
The Mann-Whitney test was performed for statistical analysis of EAE disease. This 
non-parametric rank sum test was chosen because the measurements of EAE scores 
are discrete. Previous reports from the Anderton group have also made use of the 
Mann-Whitney test and the results have been used and accepted [99; 260]. 
In statistical analysis of cell surface ligand expression and analysis of proliferation 
assay data, an unpaired student’s t test was performed. This parametric test was used 










































Testing disease models based on 
both MOG35-55 and MBPAc1-9 to 






3. Testing disease models based on both MOG35-55 and MBPAc1-9 to 





Previous work by the Anderton group made use of the C57BL/6 x B10.PL mouse 




 MHC haplotype. A striking feature of this 
F1 mouse, which sets it apart from its parental strains, is that no disease was observed 
despite the introduction of either MOG35-55 or 4Lys within a standard EAE-inducing 
immunisation. In fact disease was only observed with 4Lys if there was an adoptive 
transfer of Tg4 cells prior to the immunisation. This limitation of disease to the 
introduction of 4Lys relevant cells is advantageous in this mouse because it enables 
the tracking of the disease relevant cell population, using congenic markers such as 
CD90.1 or CD45.1 which are not present in the host animals. 
 
One of the primary aims of the experiments detailed in this chapter was to establish a 
relapsing-remitting form of EAE using both the MOG35-55 and MBPAc1-9 peptides to 
allow the observation of intermolecular epitope spreading, which has been suggested 
as the causative mechanism for RR-EAE. Intramolecular epitope spreading, with 
MBPAc1-9, was previously noted in B10.PL x SJL mice [265] and both intra- and 
intermolecular spreading, caused by PLP139-151, was noted in SJL mice [267]. 
 
A second goal was to establish EAE in C57BL/6 x B10.PL mice without the use of 
transgenic cells. This would provide the opportunity to examine EAE with a diverse 
repertoire of T cells expressing different TCR.  This system could then be exploited 
to enable the examination of the effects of molecular mimicry in EAE; by using a 
superagonist APL to mimic a strong stimulus given by a foreign antigen and create 
an antigen experienced cohort of cells which could be challenged at a later time point 




This model could be used to clarify the mechanisms of peripheral tolerance by 
allowing the examination of the fate of a 4Lys experienced T cell repertoire after a 
challenge with superagonist peptide. Is the immune system able to maintain the 
repertoire and avoid deletion of cells bearing TCR that may be required at a later 





























3.2. Developing a model to study the contribution of MOG or MBP peptides 
to epitope spreading 
 
In an attempt to develop a model to observe epitope spreading using MOG35-55 and 
4Lys, transgenic cells bearing TCR relevant to these peptides (2D2 [43] and Tg4 [49] 















 cells were transferred 
together into C57BL/6 x B10.PL mice. These mice were subsequently immunised 
with either the MOG35-55 or MBP 4Lys peptides (Fig. 3.1A). 
 
Only 50% of 4Lys immunised mice showed signs of EAE with 25% of the total 
group reaching a fatal clinical score; the remaining mice showed low levels of 
disease. Clinical signs of EAE were observed in 75% of the MOG35-55 immunised 
mice (Fig. 3.1B). A small number of mice immunised with MOG35-55 relapsed with 
mild disease (mean score 1) around day 30. 
 
Lymph nodes, spleen and CNS were taken from sick mice at day 8 of disease; cells 
were stained for flow cytometric analysis to enable tracking and to observe 
phenotypic changes. These mice were excluded from the time course analysis 
because scoring for clinical signs of disease in this experiment only began at day 7 
(Fig 3.1B). Despite the observation of disease in both immunisation groups the flow 
cytometric analysis showed that no 2D2 cells could be tracked within the C57BL/6 x 
B10.PL mouse. Tg4 cells were however not only present in both immunisation 
groups but were also seen to be enriched within the CNS; Tg4 cells were also present 
in the lymph nodes and spleen of the non-immunisation control mice (Fig. 3.2). 
 
 
3.3. MOG35-55 relevant TCR transgenic cells fail to survive adoptive transfer 
into C57BL/6 x B10.PL mice 
 
The lack of visibility of the 2D2 cells in either immunisation group suggested that 
these cells were not surviving transfer into the C57BL/6 x B10.PL mouse. 
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 cells after adoptive transfer into the C57BL/6 x B10.PL and the C57BL/6 
mouse. 
 






 cells into either C57BL/6 or 
C57BL/6 x B10.PL mice was followed, after 24 hours, by immunisation with 
MOG35-55 (Fig. 3.3A); tissue samples were analysed prior to immunisation. Even at 
this time point (day 1), analysis of the lymph nodes of the C57BL/6 x B10.PL mice 
showed a 58% reduction in the frequency of 2D2 cells compared to those of the 
C57BL/6 mice. This difference fell to 37% in the spleen (Fig. 3.3B). At day 5 post-
cell transfer (4 days post-immunisation), 2D2 cells in the C57BL/6 mice showed an 
expansion in numbers in both lymph nodes and spleen whereas the C57BL/6 x 
B10.PL mice showed no expansion; with the frequency of 2D2 cell remaining similar 
to day 1 figures (Fig. 3.4).  This was consistent with day 8 data where C57BL/6 x 
B10.PL mice showed a 99.5% and 93.75% reduction in 2D2 cell frequency in the 
lymph node and spleen respectively compared to C57BL/6 mice.  
 
 
3.4. C57BL/6 x B10.PL APC are capable of stimulating 2D2 CD4
+
 cells in 
vitro 
 




 cells was due to a lack of in vivo 
stimulation in the C57BL/6 x B10.PL mice, 2D2 proliferation assays were carried 
out using irradiated and non-irradiated APC from both the C57BL/6 x B10.PL and 
the C57BL/6 mice. Lymph nodes and spleen were taken from 2D2 mice and were 
positively selected for CD11c; the negative fraction from this selection was then 
positively selected for CD4
+






 cells were added to 10
5
 
C57BL/6 x B10.PL or C57BL/6 irradiated or non-irradiated APC (Fig.3.5A). 
Irradiated APC groups were included to show that proliferation was not a result of 
expansion of the C57BL/6 x B10.PL or C57BL/6 cell populations. After 30 hours 
cells were pulsed with 
3
H (thymidine), the incorporation of this was used as readout 
of proliferation and was measured as counts per minute (cpm) at 48 hours (Fig.3.5B). 
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Although data show a 50% reduction in proliferation of 2D2 cells with APC from 
C57BL/6 x B10.PL compared to those from C57BL/6 (at 5µg/ml of peptide) there is 
no significant difference observed between the proliferative potential of 2D2 cells 
with either irradiated or non-irradiated APC from each strain (unpaired t test). The 
data show that proliferation occurs when antigen is presented to 2D2 cells by 
C57BL/6 x B10.PL in vitro indicating that 2D2 cells have the potential to be 
stimulated in C57BL/6 x B10.PL mice. Increased proliferation with non-irradiated 
APC can be explained by the active MOG35-55 relevant host repertoire of CD4
+
 cells 
that exists in the C57BL/6 mouse. 
 
 
3.5. Developing a passive transfer model for the C57BL/6 x B10.PL model 
 
Due to the poor viability of 2D2 cells within the C57BL/6 x B10.PL mouse, the 
behaviour of a MOG35-55 relevant repertoire of T cells had to be analysed via a 
different protocol. A previously published passive transfer protocol, from O’Connor 
et al, was modified for using the C57BL/6 x B10.PL mice as the source of both cells 
- donor and host [268]. C57BL/6 x B10.PL mice were immunised with 100µg of 
MOG35-55 in CFA and were then left for 10 days before inguinal and para-aortic 
lymph nodes were removed. The cells from these nodes were cultured for 72 hours 
with MOG35-55, IL-2, IL-12 and IL-18 to polarise the CD4
+
 cells into Th1 type CD4
+
 
cells. At day 3 the cells were transferred into naïve F1 mice followed by two shots of 
PTx, one on the same day and another 2 days later (Fig 3.6A). 
 
Immunisation of mice with peptide and CFA leaves a long-term depot of antigen for 
cells to be continually activated from. This can cause disease even after a primary 
course of T cell activation and therefore potentially after disease recovery has 
occurred; passive transfer models eliminate this problem. 
 
The data show that the in vitro polarised cells do cause disease in the C57BL/6 x 
B10.PL mice; this disease was monitored for 14 days. Clinical signs of EAE first 
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appear at day 5 (2 days earlier than that seen in the traditional actively induced model 
of EAE - peptide + CFA + PTx), with the peak of disease at day 10. The maximum 
clinical score seen in any one mouse was grade 3 and the mean maximum clinical 
score was 2.25 (Fig 3.6B). 
 
The in vitro stimulation was repeated with naïve Tg4 cells; 5x10
6
 blasting cells were 
transferred into C57BL/6 x B10.PL alongside two doses of PTx (Fig 3.7A). These in 
vitro stimulated Tg4 cells were highly pathogenic. Disease course shown is a 
compilation of two different experiments; once again, disease began at an early time-
point (relative to an active induction of EAE - at day 5 rather than at day 7) however 
in this passive model disease lasts for at least 20 days (Fig 3.7B). The maximum 
clinical score seen in any one mouse, receiving stimulated Tg4 cells, was 5 with the 
maximum mean group clinical score of 3.5. Mice that were given ‘unstimulated’ 
(naïve) Tg4 cells did not present with any clinical score throughout the 25 day 
period. Mice from both passive and naïve transfer were culled at day 16 and spleen 
and CNS were processed for flow cytometric analysis. Data show that out of all 
CD4
+
 cells in the spleen the mean number of Tg4 cells was 8.59%; this number 
increased dramatically to 57% of total CD4
+
 cells when CNS was examined (Fig. 
3.8A). These observations were repeated at day 25 when the experiment was 
terminated due to excessive weight loss in the mice(Fig. 3.8B).  
 
Further experiments attempted to track in vitro stimulated 2D2 cells within the 
C57BL/6 x B10.PL on the assumption that in vitro stimulated (and therefore 
previously activated) cells would have an advantage in terms of viability and 
pathogenicity to naïve adoptively transferred 2D2 cells. However, as in previous data 
from the adoptive transfer of 2D2 into the C57BL/6 x B10.PL model, very few of 
these cells survived the transfer when compared to transfer into the C57BL/6 mouse 
(Fig 3.9).  
 
In an attempt to prevent any possible rejection of the 2D2 cells from the C57BL/6 x 
B10.PL system, an F1 mouse was produced by crossing 2D2 mice with B10.PL mice. 
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Cells from these F1 mice were passively transferred into the C57BL/6 x B10.PL 
mice, once again the 2D2 cells showed poor viability as shown by Figure 3.10. 
 
 
3.6. Developing a non-transgenic model of EAE in C57BL/6 x B10.PL  
 
As mentioned earlier, C57BL/6 x B10.PL mice do not show clinical signs of EAE 
after a single immunisation alone, with either MOG35-55 or 4Lys, and indeed that was 
the previous dogma. Experiments in our laboratory have recently described the 
induction of EAE using a double-immunisation protocol using MOG35-55 peptide in 
C57BL/6 mice [269]. Peptide is introduced with 60µg CpG and IFA into one hind 
leg and is followed 28 days later with peptide and CFA into the other followed by the 
intraperitoneal administration of PTx to induce EAE. 
 
The peptide used here was 4Lys (Fig. 3.11A). 75% of the mice showed clinical signs 
of EAE, with a mean peak clinical score of 2.75 (Fig. 3.11B) with a mean duration of 
8.5 days. The proliferation of splenocytes from these mice was normal when tested 
against 4Lys in vitro (Fig. 3.11C). These data show that a double-immunisation 
























The experiments outlined in this chapter represent attempts to establish RR-EAE 
models of EAE with the MOG35-55 and MBPAc1-9 peptides which were unsuccessful. 
Disease was so severe in 25% of mice immunised with 4Lys that these mice showed 
no recovery for the duration of the experimental time course; those immunised with 
MOG35-55 became ill, showed good recovery and a small number relapsed with mild 
disease (mean score 1) around day 30 (Fig. 3.1). Epitope spreading is more clearly 
indicated by data showing that the immunisation of C57BL/6 x B10.PL mice with 
MOG35-55 allowed the entry and expansion of MBPAc1-9 relevant cells in the CNS 
(Fig. 3.2); suggesting that MBP was released from the CNS and allowed the homing 
of the relevant cells. This would have been more clearly defined had analysis of 
CD44 expression (a marker of antigen experienced cells) been investigated.  
 
Other data exist showing that epitopes of MOG, specifically MOG92-106, can be used 
within bystander activation models in SJL mice to induce relapses against secondary 
myelin epitopes which are accompanied with extensive B cell reactivity [270]. 
Future experiments examining the potential of MBP and MOG related epitope 
spreading would benefit from the analysis of antibody class switching; class 
switching would indicate a shift in B cell reactivity and therefore a switch in the 
repertoire of T cells mediating disease. 
 
The data presented in this chapter show the strong viability of the Tg4 cells after 
transfer into other histocompatible (H-2
u
) strains. In each transfer of these cells, 
disease was manifested and cells could be tracked and found to be enriched in the 
CNS. None of the experimental data presented here show that 2D2 cells can match 
the viability, traceability and proliferative potential of the Tg4 system during disease, 
if in fact disease is manifested at all. 
 
The reduced ability to induce disease, shown in Figure 3.1, cannot be accounted for 
by the suggestion that there is a problem with antigen presentation by C57BL/6 x 
B10.PL APC to 2D2 CD4
+ 
cells.  In vitro assays comparing the proliferative 
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potential of 2D2 cells against APC from C57BL/6 mice or C57BL/6 x B10.PL mice 
show that although the potential is lowered in the latter strain, it is still strong. 
 
This is further supported by the successful development of the passive transfer model 
using MOG35-55 within C57BL/6 x B10.PL mice where a MOG35-55 immunisation is 
used to produce an antigen experienced cohort of cells within F1 mice, which when 
stimulated in vitro and then transferred can induce disease in the same mice.  
 
The reasons for the poor survival of the 2D2 cells are unclear. They were bred onto a 
C57BL/6 background and therefore should have the capacity to survive C57BL/6 x 
B10.PL hosts. Transfers of the 2D2 cells into C57BL/6 mice have not been seen to 
be successful in inducing disease although flow cytometric analysis from the 
Anderton group has been able to track their movement into the CNS (M. Leach, 
personal communication); however doubts remain as to whether their migration to 
the CNS is antigen specific. Another feasible option is that the 2D2 cells are being 
killed off by NK cells within the C57BL/6 x B10.PL mice. NK cells have inhibitory 
receptors that scan cells for low levels of MHC; cells such as these can be killed off 
via perforin and granzymes. 
 
Although Paterson [29], is credited with the initial passive transfer of EAE with 
lymph node cells, the technique most commonly used today is based on work, in SJL 
mice, by Pettinelli et al in the 1980s [271]. The passive transfer model serves as a 
powerful tool to examine the progression of disease. This method of EAE induction 
separates the induction phase (immunisation) from the effector phase (disease 
progression) by confining each phase to separate groups of animals. The model’s 
advantages include the elimination of the presence of non-disease relevant antigens 
(from Mycobacterium tuberculosis in CFA) and may be considered ‘cleaner’ because 
the induction of disease occurs through the transfer of only the disease inducing 
cells, in the absence of antibody and antigen. It also allows for more direct tracking 
of the disease relevant cells.  
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Disadvantages include the requirement for an in vitro tissue culture stage and the 
increased numbers of mice required as well as the large amounts of peptide needed 
for both immunisation and in vitro challenge, relative to active induction alone. Also 
there is a greater temporal cost, the induction phase in host mice takes 10 days 
followed by a further 3 days in vitro before the cells can be transferred. In the data 
shown here the time for a clinical score to be observed after immunisation in passive 
induction is 18 days compared to 7 days in active induction. 
 
The development of the double-immunisation protocol within the 4Lys / C57BL/6 x 
B10.PL model is important in allowing the progression of disease without the 
requirement for transgenic cells seen previously [269]. This system can be used in 
allowing the examination of the induction of tolerance in an antigen experienced 
cohort of host cells and combined with the MBPAc1-9 APL system allows the 
investigation of molecular mimicry within C57BL/6 x B10.PL mice.  
 
This chapter focuses on attempts to define a RR-EAE model using the MBPAc1-9 and 
MOG35-55 epitopes which were unsuccessful due to the poor viability of the 2D2 
transgenic cells. The chapter describes the successful modelling of passive disease 
using MOG35-55 to prime host cells in vivo and in vitro. The Tg4 cell passive transfer 
model is also defined as well as a dual immunisation protocol, both of which were 





































































































































































































































































































































































































































































































































































































































































































Developing a model to examine 

























The progression of RR-MS and RR-EAE is a cyclical process created by the positive 
and negative feedback nature of the immune system. Immunological cycles depend 
on the mechanisms which control clonal expansion and death of disease relevant 
cells. The phenomenon of epitope spreading has long been implicated within the 
relapsing-remitting course of multiple sclerosis and its animal model, EAE [265, 
267]. The destruction of the myelin sheath, due to the focus of the immune response 
on an initial dominant epitope, leads to the release of other cryptic epitopes against 
which different pathogenic T cells can react. Consequently the focus of the immune 
response deviates and relapses are seen. One of the few positive aspects of epitope 
spreading may be the potential that antigen release may allow the progression of 
bystander suppression [272].  
 
Anderton and Wraith [259] first addressed the question of whether the MBPAc1-9 
APL, 4Tyr [50, 256] could suppress disease induced with the wild-type I-A
u
-
restricted 4Lys or with the I-A
s
-restricted epitope PLP139-151. Evidence from 
experiments involving the intra-nasal administration of 4Tyr, prior to EAE induction 
with whole myelin, showed that the APL treatment was able to suppress disease 
induced with 4Lys and MBP89-101 (intra-molecular suppression) but was ineffective at 
suppressing disease with PLP139-151 (inter-molecular suppression).  
 
The situation was reversed when the I-A
s
-restricted PLP139-151 was administered prior 
to EAE induction with either whole myelin or with MBP derived epitopes; disease 
was suppressed and T cells showed reduced proliferative potential against all three 
peptides. Worthy of note is the fact that lymph node responses to MBP were only 
suppressed by the PLP139-151 treatment when EAE was induced by whole myelin 
rather than the individual peptides. The use of whole myelin, containing many more 
epitopes than the three used initially, shows that PLP139-151 has a wide-ranging 
 87 
capacity to suppress disease. Anderton et al concluded that the requirement for whole 
myelin suggested a need for co-presentation of PLP139-151 at the same time and site 
for suppression to occur. 
 
Although a switch from a Th1 to Th2 cytokine milieu was not supported by the data 
from that previous study, the disparity in the ‘bystander suppression’ may be 
explained by the precursor frequency of T cells reactive to the MBP or PLP139-151 
epitopes. Whereas PLP139-151  is conserved within the CNS, MBP is known to be a 
component of the sheath in peripheral nerves [273] and data show that it may be 
presented in the thymus of a young mouse [274] – both these factors would help to 
reduce the frequency of MBP-reactive cells. We know that there is a much higher 
frequency of PLP139-151 relevant T cells in the periphery, as they are able to escape 
from thymic selection [236]. This failure is due to the expression of DM20 in the 
thymus, a spliced variant of PLP with a deletion at residues 116-150 [275]. 
 
This lower initial frequency of cells reactive to MBP means that fewer regulatory 
cells may be induced by the 4Tyr peptide treatment in comparison to the PLP139-151 
treatment. This may in turn help to explain the less potent inter-molecular 
suppressive effect of the 4Tyr. 
 
Lower numbers of 4Lys reactive cells can be compensated for with the introduction 
of MBPAc1-9 relevant Tg4 transgenic cells [49] and in this chapter Tg4 cells were 
used in combination with the H-2
u,s 
B10.PL x SJL mouse to develop a model of 
EAE. This model has been used to evaluate the potential of tolerised transgenic cells 
to limit the severity of disease induced with a different myelin auto-antigen. Previous 
studies from the Anderton group have shown a relapsing-remitting form of disease in 
B10.PL x SJL mice immunised with the 4Lys  epitope [276].  
 
The work discussed below focuses on disease induced with the PLP139-151 epitope in 
B10.PL x SJL mice and the findings therein that the transfer of Tg4 cells enhances 
single phase disease to a relapsing-remitting state. Furthermore the question of 
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whether the tolerisation of the Tg4 cell population could ameliorate disease induced 
































4.2. The transfer of Tg4 transgenic cells causes a relapsing-remitting in 
B10.PL x SJL mice 
 
Tg4 cells, purified using MACS positive bead selection for CD4, were adoptively 
transferred into B10.PL x SJL (H-2
u,s
) mice in order to investigate the possibility that 
disease induced by PLP139-151 could diverge to the Tg4 relevant 4Lys epitope, after an 




 and therefore 
in later experiments Tg4 cells, lacking CD45.1 could be tracked using flow 






 Tg4 cells were transferred into B10.PLxSJL mice which 
were subsequently immunised with 200µg of PLP139-151 (Fig 4.1A). Two control 
groups were also set up, the first was immunised with PLP139-151 but was not given 
the Tg4 cell transfer and the second was given a transfer (1x10
6
 Tg4) but no 
immunisation. The mean clinical score was monitored for a period of 55 days 
following immunisation to attempt to track further relapses however no disease was 
observed beyond day 35 (Fig 4.1B). 
 
Disease course analysis showed that only mice that received both Tg4 transfer and 
PLP139-151 immunisation showed a relapsing-remitting course of disease. Those that 
received only immunisation showed a single phase of disease with no relapse. This 
alone suggested that the Tg4 cells that had been transferred were in some way 
responsible for the relapses seen. The first phase of disease was not significantly 




 Tg4 cells were transferred 
despite the earlier recovery observed in mice given 0.5x10
6
 cells (Fig 4.1; Mann-
Whitney Test; p = 0.2949). Mice that received immunisation alone also showed a 
non-significant difference compared to those receiving 1x10
6 
Tg4 cells (Fig 4.1; 
Mann-Whitney Test; p = 0.3337). 
 
Repeat experiments, this time using 4Lys immunisations, as positive controls for RR-
EAE, showed similar disease patterns as in Figure 4.1. PLP139-151 immunised mice 
were scored over a period of 45 days. During the primary phase of disease, starting at 
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around day 10 and finishing around day 25 there was no significant difference 
between the immunised groups which received Tg4 cells and those that did not (Fig 
4.2; Mann Whitney Test; p = 0.1576). It was the period of time between day 25 and 
day 35 that showed significant difference in total disease course (Mann Whitney 
Test; p = 0.0170). Relapses in disease were only observed in groups where Tg4 cells 
had previously been transferred (Fig 4.2). The 4Lys control immunisation result in 
the rapid death of the immunised animals (within a period of 15 days) so the entire 
disease course could not be monitored for full comparison to the PLP139-151 
immunisations. These data suggest that Tg4 cells are having an impact on the course 
of disease in this PLP139-151 / B10.PLxSJL model of EAE.  
 
 
4.3. Epitope spreading to the 4Lys epitope is not observed in PLP139-151 
induced disease 
 
To determine the likelihood of Tg4 cells having an active effect on the course of 
disease, as suggested above, Tg4 cells were adoptively transferred into B10.PL x SJL 
mice which were subsequently immunised with either 4Lys or PLP139-151. Lymphoid 
organs and the CNS were analysed by flow cytometry on day 14, with the 
proliferative potential of splenocytes being tested in vitro.  
 
Figures 4.3A and 4.4 show that at peak of disease where one would predict 
maximum inflammatory infiltrate, day 14, there was a significant enrichment of Tg4 
cells within the CNS of 4Lys immunised mice when compared to the peripheral 
lymphoid organs. Mice immunised with PLP139-151 however showed no enrichment in 
the CNS. 
 
Spleens were taken from animals after recovery from relapse (day 35 - Fig 4.5) and 
cells were challenged in vitro with varying concentrations of 4Lys or PLP139-151. 
After 72 hours cultures were pulsed with 
3
H (thymidine), the incorporation of this 
was used as readout of proliferation and was measured as counts per minute (cpm). 
Responses against PLP139-151 were similar in all groups, even where no Tg4 cells had 
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been transferred confirming that these cells have no impact on the host immune 
response against the PLP139-151 peptide. No significant responses were seen when 
splenocytes were challenged with the 4Lys peptide, even at high concentrations (Fig 
4.5B). 
 
4.4. Administration of soluble 4Tyr ameliorates disease in the Tg4 / B10xSJL 
model 
 
In an attempt to manipulate the Tg4 cells in this model and in turn manipulate the 
effect these cells would have on the course of disease, 1x10
6
 Tg4 cells were  
transferred into B10.PLxSJL mice and then 4Tyr in PBS was administered to attempt 
to tolerise the cells in vivo seven days prior to a PLP139-151 immunisation (Fig 4.6A), 
the protocol being based on previous work by Anderton et al [259]. In a separate 
group of mice PLP139-151 was used with PBS in a tolerising protocol in EAE induced 
by 4Lys (Fig 4.7A). These mice received Tg4 cells at a later timepoint to those 
treated with 4Tyr because they would not have had stimulus to survive in vivo in the 
absence of a relevant antigen. Mice were scored for disease for a period of 40 days 
after immunisation. 
 
Mice that were given 4Tyr after the Tg4 transfer showed a significantly different 
course of disease (p<0.0001; Mann-Whitney Test) to those that received the PBS 
alone over several experimental time courses. Data from two separate experiments 
were collated for disease score and is shown in Figure 4.6B. In both groups, clinical 
signs of disease were observed at day 5 and were of similar severity and duration. 
The first relapse in the 4Tyr treated group is observed on day 42 (22 days after the 
non-treated group) with only 2 out of 15 mice relapsing with a mean clinical score of 
0.5. Non-4Tyr treated mice had a mean clinical score of 1 during relapse (6 of 12 
mice relapsed). None of the mice treated with 4Tyr presented signs of a further 
relapse, with the caveat being that mice were culled at day 70 and may have relapsed 
at a later time point that this (Fig 4.8A & B). The data show more than one relapse in 
the mice that were treated with PBS alone, at days 38 and 51; this was not seen in 
previous experiments in which disease was only monitored till day 35. 
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In mice treated with PLP139-151 and PBS and subsequently immunised with 4Lys (Fig 
4.7A), the initial phase of disease was lower in severity than those mice given only 
PBS (Fig 4.7B). The severity of the primary relapse was similar between groups and 
a secondary relapse was only seen in the mice treated with PLP139-151, again with the 
caveat that the disease course was only monitored for a period of 40 days. 
 
 
4.5. MBPAc1-9 relevant Regulatory T Cells can be seen in the CNS of PLP139-
151 immunised mice 
 
In order to explain the differences in disease course seen above and to assess the 
effects the 4Tyr on the transferred Tg4 population of cells we culled mice during the 
recovery of the primary phase of disease (day 14) and cells from the inguinal and 
paraortic lymph nodes, spleen and CNS were taken and stained for flow cytometry 
analysis with Tg4 cells in this transfer model traceable because of their lack of the 
CD45.1 marker. 
 
In animals not given 4Tyr (prior to cell transfer and immunisation) Tg4 cells did 
appear to be present in the spleen (Fig 4.9A). However the flow cytometry staining 
suggested that there were no transgenic cells present in either the lymph nodes or the 
CNS (Fig 4.9A & Fig 4.10A). Similarly animals treated with 4Tyr showed few Tg4 
cells present in the lymph nodes and spleen (Fig 4.9A). However, in contrast to the 
PBS treated mice, CNS samples from the 4Tyr treated mice showed a distinct 
population of Tg4 CD4
+
 cells (Fig 4.10B). The staining showed a 5-fold enrichment 
of cells within the CNS compared to the spleen sampled (0.99% of total CD4
+
 cells 
in the CNS compared to 0.18% in the spleen). Although t test analysis of the data 
suggests no significant difference, our flow cytometry observations clearly indicate a 
defined population of Tg4 cells in the CNS of the 4Tyr treated mice (Fig 4.10B) 
whereas the PBS treated mice (Fig 4.10A) showed no greater degree of staining than 
the control sample (Fig 4.10C). 
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Further analysis of this infiltrating population of Tg4 cells showed that a mean of 
45% of these cells expressed Foxp3 (Fig 4.9B & Fig 4.11). Analysis of the host 
populations of both groups of mice showed no significant difference in the size of the 
host regulatory T cell population (Fig 4.9C: p=0.4548; unpaired t test). To check if 
cells were unable to migrate to the CNS we obtained flow cytometry data on CD69 
and CD49d (VLA-4 – required for cell migration to the CNS) expression within the 
lymph nodes. We also analysed expression of CD44 in the CNS. None of these 
analyses revealed any difference in expression between the two groups of mice (data 
not shown).  
 
Splenocytes from the animals, again taken at day 14, were cultured with either 4Tyr 
or PLP139-151 overnight and subsequently stained to measure the production of either 
IFN-γ or IL-17. Although no differences were seen between the groups, the in vitro 
challenge with the PLP139-151 produced a greater amount of both IFN-γ and IL-17 in 































Epitope spreading has generally been accepted to be a result of the progression of the 
immune response from one epitope to another [267] resulting in multi phase disease. 
Early experiments in this laboratory modelled relapsing-remitting EAE using B10.PL 
x SJL mice immunised with the MBP epitope 4Lys [276]. 
 
Here, MBPAc1-9 relevant Tg4 cells were transferred into animals immunised with 
PLP139-151 in order to examine the possibility of an intermolecular spread of disease 
(from PLP139-151 to 4Lys). The presence of relapses clearly implicate the transferred 
Tg4 cells in mediating some aspect of disease; whereas the normal PLP139-151 
immunisation shows no relapse, the introduction of Tg4 cells changes the single 
phase disease course to a characteristic relapsing-remitting disease course. 
 
Paradoxically, the data showed no evidence of a response to the 4Lys peptide from 
cells taken from these PLP139-151 immunised mice. The Tg4 cells transferred into 
mice immunised with PLP139-151 showed comparatively little migration into the CNS 
when examined alongside mice immunised with 4Lys. Splenocytes, from mice 
immunised with PLP139-151, showed poor proliferative potential, comparable to 
negative controls, when challenged in vitro with 4Lys.  
 
This may be explained by recent work which attempts to define the location at which 
epitope spreading occurs. By introducing CFSE labelled PLP139-151 relevant 
transgenic cells into mice immunised with PLP178-191, McMahon et al [277] observed 
that these cells did not proliferate in the peripheral lymphoid compartments but 
showed extensive proliferation in the CNS. As expected, they did proliferate well in 
both periphery and CNS of mice immunised with PLP139-151. Flow cytometric 
analysis of activation markers confirmed these data to suggest that epitope spreading 
occurs primarily in the CNS and not in the periphery. These observations may help to 
explain why the splenocyte proliferation data shown in this chapter shows no 
evidence of a 4Lys response. 
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The previous dogma would predict that the Tg4 cells would have been activated by 
APC in the peripheral lymphoid compartments and would then be recruited into the 
CNS. In contrast to this, McMahon’s conclusion suggests that naïve Tg4 cells would 
need to migrate to the CNS during the first phase of PLP139-151 induced disease to be 
presented with 4Lys by APC. This may support some of the data in this chapter in 
that some migration of Tg4 cells into the CNS in PLP139-151 induced disease is 
observed. The marked increase in Tg4 numbers in the 4Lys immunised mice due to 
an almost immediate expansion of these cells in the periphery can explain their larger 
population in the CNS compared to those mice immunised with PLP139-151. 
It may be feasible that the small number of Tg4 cells that do travel to the CNS 
mediate enough damage to reveal other disease mediating epitopes. It seems likely 
that relapses would follow the hierarchal pattern established in SJL mice, firstly 
directed against PLP178-191 and then against MBP89-101 [267]. It may also be feasible 
that the Tg4 cells travelling to the CNS create a cytokine milieu that is effective in 
activating surrounding cells which in turn mediate disease. 
 
Previous studies have described that soluble peptides are an effective means of 
limiting the pathogenicity of certain autoimmune diseases including EAE [258], 
arthritis [278] and diabetes [279]. The mechanisms of tolerance have not fully been 
identified however. Anderton and Wraith [259] demonstrated the potential of using 
soluble peptides in conjunction with the MBPAc1-9 APL system in the B10.PLxSJL 
mouse. They were unable however to show that the 4Tyr APL could suppress disease 
induced by PLP139-151.  
 
The tolerisation of B10.PLxSJL mice with PLP139-151 has been repeated here with 
several changes; the tolerising peptide was administered i.v with PBS rather than i.n. 
and Tg4 cells were administered. The primary phase of disease is remarkably similar 
to that seen by Anderton and Wraith. However in a change to their observations, the 
data in this chapter show relapses in both PLP139-151 treated and PBS treated mice can  
recovery fully from disease between the relapses with the introduction of Tg4 cells.  
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The experiments shown here overcome the numerical limitations of previous work 
by artificially increasing the precursor frequency of T cells relevant to 4Lys through 
the introduction of Tg4 cells which bear the moderate affinity receptor for 4Lys. The 
data show that 4Tyr treatment in this scenario is not able to limit the severity of the 
initial phase of disease caused by PLP139-151 but does substantially delay the onset of 
relapse. This in turn supports the notion that the Tg4 cells are relevant to relapses as 
when they are ‘silenced’ there is no relapse. Further investigations into the hierarchy 
of epitopes to which the immune response is directed to cause relapses in disease 
would address the question of whether the relapse has been delayed or if a relapse 
directed at a certain epitope is missing in 4Tyr treated mice - hence no disease in the 
time frame where non-4Tyr treated mice relapse. 
 
The data show the presence of Tg4 CD4
+
 cells within the CNS. The Foxp3 marker is 
expressed on 3 to 5% of naïve Tg4 cells pre-transfer (S. Anderton, unpublished 
observations). However, here 45% of the Tg4 cells in the CNS expressed Foxp3. 
This suggests that either the Tg4 Tregs have been recruited to the CNS and expanded 
or that Tg4 CD4
+
 cells have migrated to the CNS and been converted into Tregs 
expressing the Foxp3 marker due to the milieu present in that tissue. Either way, the 
presence of these Foxp3 cells suggests that they may be responsible for limiting the 
















































































































































































































































































































































































































































































































































































































































































































































































Investigating the Role of 
Adaptation in Limiting 

























Due to the cross-reactive nature of the TCR, a single T cell has the ability to respond 
to epitopes from both infectious agents and self tissue [153, 154]. One of the factors 
suggested to initiate autoimmune disease is molecular mimicry. The molecular 
mimicry theory suggests that an immune response initially directed at a non-self 
antigen by a T cell can spread to a self antigen because of the cross-reactivity of the 
TCR [153, 228]. A reversible state of unresponsiveness, an ability of T cells to tune 
themselves to stimulus, could prove beneficial within the immune system as a means 
of limiting the risk of autoimmune disease through molecular mimicry  [161]. 
 
Adaptation can be quintessentially summed up as in vivo anergy [207, 220]. There 
are however significant differences between anergy and adaptation, primarily the 
latter requires persistent stimulation, although further differences do exist at the 
molecular level of T cell signalling. Once the stimulus is removed the cell can return 
to a normal state of responsiveness [220]. Although Grossman and Paul [217] put 
forward the TAT model to explain the ability of T cells to maintain tolerance to self-
MHC-peptide complexes by tuning their TCR signalling to match the background 
level of stimulus, the mechanism behind this is still largely unknown. The down-
regulation of TCR signalling would in turn make a T cells harder to stimulate with 
subsequent challenge. 
 
Ryan et al [174] initiated the approach that is expanded upon in this chapter, through 





II molecules. Previously it had been shown that substitutions at position 4 of 
MBPAc1-9 result in variations in binding strength with I-A
u
; with the tyrosine 




In vitro these differences in affinity relate directly to antigenicity, so that the stimulus 
provided by the 4Tyr peptide is that much greater than that provided by the 4Lys 
peptide. As a result these APL can be used to provide varying levels of stimulus to 
transgenic Tg4 T cells (of a fixed moderate TCR affinity) and thereby allow the 
investigation of how the T cells react to changes in strength of stimulus. 
 
In vivo, the immunisation of 4Tyr was seen to cause apoptosis in 70% of cells 
compared to just 10% with 4Lys immunisation [280]. Ryan et al [174] used in vitro 
analysis of these cells to show that this was activation-induced cell death as a result 
of Fas and FasL expression by the T cells. This was then translated into the H-2
u x b 
mouse; as expected ‘normal’ Tg4 cells in conjunction with a 4Tyr immunisation 
failed to induce EAE whereas Fas-deficient Tg4 cells were able to induce EAE. 
However the level of disease induced was considerably less severe than that seen 
with a 4Lys immunisation. The fact that Fas-deficient Tg4 cells were unable to cause 
more severe disease opened the possibility that other mechanisms were acting to 
maintain tolerance. Further in vitro analysis confirmed in vivo findings that not all 
Tg4 cells died after challenge with 4Tyr. These remaining Tg4 cells were reduced in 
their proliferative potential against 4Lys and 4Tyr in a dose-dependent manner. This 
functional desensitisation correlated with enhanced CD5 expression [174].  
 
CD5 has been previously shown to have a role in MOG35-55 induced EAE; the 
upregulation of CD5 correlated with T cell unresponsiveness to the MOG35-55  
peptide [281, 282], a second study showed the resistance of CD5 knock-out mice to 
the induction of EAE. CD5 is known to regulate Fas expression and the absence of 
CD5 may have led to increased AICD within the disease relevant population of T 
cells.  Knowing that CD5 works in conjunction with the molecules involved in TCR 
signalling, including CD4 and Zap70 [223, 224], it is entirely feasible that CD5 may 
exert its effects by dampening the level of signalling at the TCR and therefore 
reducing the activation potential of the relevant T cell. 
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The strength of signal 1 depends on the avidity of the pMHC complex to the T cell 
which in turn is based on the intrinsic affinity of the TCR for the pMHC complex, 
the density of the TCR and the density of the pMHC complexes [157]. The previous 
dogma predicted that (a) if the antigenic signal is too strong then relevant cells will 
die, (b) if the signal is too weak then the relevant cells are ignored and (c) if the 
signal is just right then the population of relevant cells will be expanded [161]. In 
both (a) and (b) the T cells cannot reach their full autoaggressive potential to mediate 
disease. However in (c) disease is able to develop.  
 
This chapter investigates the effects of a strong antigenic signal on a population of T 
cells bearing moderate affinity TCR (Tg4 cells) and addresses whether this 
stimulation can lead to the functional desensitisation (adaptation) of T cells and how 
these changes limit the potential of auto-reactive T cells to become autoaggressive. 
 
Investigating adaptation in the immune system is essential within T cell mediated 
autoimmune disease because it can help to explain the mechanisms by which the 
autoreactive T cell repertoire’s sensitivity is kept below a ‘threshold for harm’ (the 
concentration of antigen required to make the autoreactive cells autoaggressive). This 
chapter develops the in vitro model and investigates the mechanisms behind 
adaptation in vivo. It expands on the observation that not all antigen relevant T cells 
die in a situation where the signal 1 is too strong in order to prevent pathogenicity 












5.2. MBPAc1-9 superagonist APL, 4Tyr, is unable to induce disease in the 
C57BL/6 X B10.PLmouse despite the transfer of transgenic cells. 
 
As shown by Ryan et al, the introduction of Tg4 transgenic cells into the C57BL/6 x 
B10.PL mouse followed by a 4Lys immunisation has the ability to induce EAE 
[174]. In this chapter the capacity of the superagonist 4Tyr peptide to induce disease 




 cells were transferred into 
C57BL/6 x B10.PL mice, which were then immunised with either 100µg of 4Lys, 
100µg 4Tyr or 10 µg 4Tyr (Fig. 5.1A). The mice were scored for clinical signs of 
EAE for 50 days (Fig 5.1B). As Figure 5.1 shows the 4Lys immunised mice 
presented with a standard course of EAE and those immunised with the high dose of 
4Tyr  showed no clinical signs of EAE until day 34, when one of the five mice 
developed signs of EAE. The disease course in the mouse lasted for 9 days in total 
reaching a maximum clinical score of 3. The fact that disease developed in this 
mouse suggests that initial immunisation may not have been fully effective in 
inducing adaptation or, to make a larger assumption, that the adaptation induced by 
the high dose 4Tyr immunisation was reversed after the 34 day period. The cells 
would then have been able to react against the 4Lys peptide present in the CNS. The 
ability to reverse its adaptive state is key to the theory that T cells have a tuneable 
activation threshold for reactivity against antigen. 
 
Interestingly, the low dose 4Tyr immunisation group showed no significant 
difference in disease course for the first 25 days when compared to the 4Lys group. 
The 4Lys group subsequently recovered from EAE whereas the low 4Tyr group 
showed a prolonged disease course and the Mann-Whitney test showed a significant 
difference between the two disease courses between days 26 and 50 (p<0.0001). The 
fact that a low dose of 4Tyr induced disease and a high dose did not confirms the 
quantitative, rather than qualitative, nature of the peptide. 
 
Mice were culled at day 50 and organs were prepared for flow cytometry. The data 
obtained does not support differences in Tg4 cell numbers between different 
immunization groups as a cause of differential disease courses. Tracking of the 
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CD45.1 marker showed Tg4 levels to be similar in all groups in the spleen (Fig 
5.2A). 
 
The failure of the Tg4 cells to mediate EAE with 100µg 4Tyr immunisation did not 
appear to be a result of regulation; the flow cytometry data (Fig 5.2B) indicated 
similar expression of Foxp3 in the transferred Tg4 cells between the high dose 4Tyr 
and 4Lys mice; hence appearing to rule out the action of regulatory T cells. There 
was however a significantly higher expression of Foxp3 in low dose compared to 
high dose 4Tyr immunisations; this may be a result of the ongoing disease in low 
dose 4Tyr immunised mice. 
 
CD5 expression appeared to be dependent on antigenic signal strength (Fig 5.2C & 
D). Tg4 cells from both of the 4Tyr immunisations showed a higher CD5 expression 
than those from the 4Lys immunisation, this may be a qualitative effect of the 4Tyr 
APL with the differences of CD5 expression by these groups explained by the 
quantitative effect of dose. In the high dose 4Tyr this difference compared to 4Lys 
was significant (unpaired t test; p = 0.0363).  
 
In vitro challenge of the splenocytes with 4Lys and 4Tyr peptides and subsequent 
intracellular flow cytometry staining showed that under all conditions the 4Lys 
immunised mice produced more IFN-γ producing cells than the mice immunised 
with low dose 4Tyr, which in turn produced more IFN-γ producing cells than the 
high dose 4Tyr mice (Fig 5.3A & C). This conflicted with the fact that the low dose 
mice were still ill at time of culling whereas the 4Lys mice had recovered from 
disease but may be because IFN-γ producing cells in the former mice are retained in 
the CNS as a result of ongoing disease. Interestingly this low dose 4Tyr group 
produced higher levels of IL-17 post in vitro challenge under all conditions, 
including with no antigen (Fig 5.3B & C), which suggests that the IL-17 may be 
responsible for the prolonged disease course in this group. The flow cytometry data 




5.3. 4Tyr adapts T cells after a single round of stimulation in vitro  
 
In order to assess the adaptation of Tg4 cells to varying levels of stimulus, over a 
given period of time, a series of in vitro experiments were performed to predict how 
the cells would react in vivo to persistent stimulation by antigen. In vitro experiments 
allowed easier monitoring of the changing phenotype and behaviour of the disease 
relevant cells.  
 
Tg4 cells were stimulated (as described in Section 2.6) in 3 cycles, or rounds, over a 
period of twenty-one days with either 10µM of the 4Lys antigen or 1µM, 0.1µM and 
0.01µM of the 4Tyr antigen (Fig 5.4). Initial experiments showed that Tg4 cells were 
unable to survive in short term cultures stimulated with 10µM of 4Tyr and 
proliferation was not sufficient to maintain cells in cultures stimulated with 1µM of 
4Lys. Each round of stimulation began with the stimulation of Tg4 cells, with 
histocompatible APC and antigen, for 72 hours. The lymphocyte fraction was then 
separated out using Nycoprep density gradient and cultured, in the absence of 
antigen, in medium containing rat concanavalin A supernatant containing IL-2 for 4 
days. The cells were then stimulated again with the same dose of peptide as before 
and entered the cycle again. Flow cytometric data was analysed prior to the next 
round of stimulation. In order to be able to compare the density of surface molecules, 
through mean fluorescence intensity (MFI), the data from each round had to be 
collated at the same time. To address this, the cultures were started sequentially, for 
example the 3-round cultures were started a week before the 2 round cultures. Naïve 
mice were culled to show data from cells that had received no peptide stimulation in 
culture. 
 
Proliferation data showed that a single round of stimulation with high dose 4Tyr was 
sufficient to reduce the proliferation potential of Tg4 cells, compared to 4Lys 
stimulation, when subsequently assayed against 4Lys (Fig 5.5A). After two rounds of 
stimulation the reduced proliferative potential of these cells was more pronounced, 
with a 2 log shift in the concentration of peptide required to initiate proliferation (Fig 
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5.5B). A third round of stimulation showed only a single log shift – similar to that 
seen after one round of stimulation (Fig 5.5C).  
 
When assayed with the 4Tyr peptide all the short term cultures appeared to react in a 
similar fashion after the first round of stimulation (Fig 5.5D). After the second round 
and third rounds, however, 4Lys cultures were seen to respond at very low 
concentrations of the peptide, starting at 0.001µM (Fig 5.5E & F) As the peptide 
concentration was increased the proliferative potential of these cells was reduced 
compared to the lower peptide concentrations. The 4Tyr cultures did not appear to 
reduce as dramatically in proliferation potential to 4Tyr challenge in these 
subsequent rounds suggesting that these cells had adapted to the stronger stimulus.  
 
 
5.4. 4Tyr induces phenotypic changes in cultured Tg4 cells 
 
Cell surface markers were evaluated using flow cytometry to identify those cells 
potentially involved in or indicative of an adaptive response. Analysis showed 
consistency with proliferation data and showed decreases in TCR levels after a single 
round of stimulation in 4Tyr stimulated cell lines whereas the 4Lys line showed an 
increase in TCR when compared to the naïve control cells shown on the x-axis (Fig 
5.6B). The decreases in TCR in the 4Tyr lines were dose dependent; the high dose 
4Tyr cell lines showed a 46% reduction of TCR compared to naïve Tg4 cells (i.e. 0 
rounds of stimulation cells shown in Fig 5.6) and a 54% reduction when compared to 
those stimulated with 4Lys. For each 10-fold reduction in the 4Tyr dose we observed 
a one-third increase in TCR levels. 
 
As Figure 5.4 shows, flow cytometric profiles were taken at day 6 during each cycle 
of stimulation. This enabled the elimination of non-relevant cells and allowed the 
examination of adapted T cells in a resting state. After a single round of stimulation, 
levels of CD5 were increased in all stimulated cell cultures when compared to the 
levels on naïve Tg4 cells (Fig 5.7A & B). There was an immediate difference 
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between the 4Tyr and the 4Lys short term cultures which became more pronounced 
after the second round of stimulation. The high dose 4Tyr cultures had a CD5 MFI 
28% greater than the 4Lys cultures after a single round of stimulation; this rose to 
67% after two rounds however analysis after a third and final round of stimulation 
showed CD5 levels in all short term cultures returning to similar levels to the naïve 
cell controls.  
 
The changes in the expression of CD5 appeared to correlate to the strength of the 
stimulus; 4Lys short term cultures showed the least increase of any cell line and in 
the other lines as 4Tyr dose increased so did the CD5 levels. Levels of CD25 and 
CD44 increased to similar amounts in all cultures, which suggested no difference in 
activation status of the cells (data not shown).  
 
The changes observed in these short term cultures presumably contribute to the 
reduced sensitivity of the T cell following superagonist stimulation; changes in cells 
stimulated with 4Lys peptide can be explained by the fact that the concentration of 
4Lys peptide introduced to these cultures is far greater than the normal levels that 
would be seen in vivo. The data suggest that the initial suppression in proliferation 
capacity of 4Tyr cultured cells is mediated by a loss in TCR. More dramatic 
suppression correlates with the later increased level of CD5, with the exact role of 
CD5 being undetermined. The fact that CD5 levels drop after a third round of 
stimulation may point to a role for the molecule only in the early onset of adaptation, 




5.5. Single round 4Tyr stimulated Tg4 cells are pathogenic in vivo 
 
Previous data from the Anderton group show that a single round of stimulation of 
Tg4 cells with 4Lys in vitro confers a pathogenicity to the cells which is manifested 
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as disease when cells are transferred into the B10.PL mouse (unpublished 
observations).  
 
This protocol was used to investigate how adapted cells acted in vivo and to ascertain 
whether in vitro adapted cells could migrate to the CNS and could thereby cause 
disease (Fig 5.8A). The question of how long a state of unresponsiveness could last 
was also addressed by this method. The same protocol for stimulating cells was used 
as described previously in Chapter 3.5.  
 
Results showed that cells stimulated with both high and low dose 4Tyr had a 
significantly greater pathogenic potential than the 4Lys stimulated cells (p=0.0152 
and p=0.0209 respectively; Mann-Whitney test). As Figure 5.8B indicates, although 
disease onset was similar between the groups, it was the point of recovery that was 
noticeably different; in the 4Lys group only one mouse was still ill after day 17 with 
a clinical score of just 1. All the mice in both superagonist stimulated groups 
presented signs of EAE till the endpoint (day 25). 
 
Tg4 cells could be tracked with the CD45.1 marker and flow cytometric analysis of 
the spleen at the peak of disease (day 14; Fig 5.9A) showed a 75.9% increase in the 
level of Tg4 cells present in the 4Lys group compared to the high dose 4Tyr group; 
this was shown to be on the cusp of significance using an unpaired t test, where p = 
0.0479. There was also a significant 3-fold increase in the 4Lys group compared to 
the low dose (p = 0.0048). Examination of the CNS showed in all groups that there 
was an enrichment of Tg4 cells in the spleen compared to the CNS however there 
was no significant difference between the groups in terms of the levels of Tg4 cells 
present. 
 
CD5 levels on Tg4 cells in the spleen were similar in all groups, with similarities 
observed in Tg4 cells recovered from the CNS also (Fig 5.9C). Tg4 cells in the CNS 
had a higher expression of CD5 compared to those found in the spleen; it may be that 
activated cells migrate to the CNS despite levels of adaptation. Lower percentages of 
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4Tyr stimulated Tg4 cells may be found in the CNS as the peptide is not expressed 
there. 
 
5.6. Repeated in vitro stimulation is required to prevent pathology in vivo 
 
Tg4 cells were stimulated for two rounds in vitro with 10µM 4Lys, 1µM 4Tyr or 
0.1µM 4Tyr.  Then, 2x106 cells were transferred into C57BL/6 x B10.PL mice and 
two doses of PTx were administered (Fig. 5.10A).  
 
Figure 5.10B shows data collated from two separate experiments. Cells stimulated 
with 0.1µM 4Tyr were able to induce EAE of a similar severity to these stimulated 
with 10µM 4Lys (no significant difference - Mann-Whitney: p = 0.6344). A dose of 
1µM 4Tyr was also able to mediate disease but to a significantly lower level than 
both the 4Lys and the low dose 4Tyr stimulated cells (Mann-Whitney: p = 0.0002 
and p =0.0009 respectively). This suggested a limited pathogenic potential of these 
cells exposed twice to 1µM 4Tyr. 
 
Tracking of the CD45.1
+
 Tg4 cells via flow cytometry showed that at the peak of 
disease, day 14, the percentage of Tg4 cells in the spleen was 50% lower in the 1µM 
4Tyr group compared to the 4Lys group; this observation was matched in the CNS 
(Fig. 5.11A). Although not shown to be significantly different (unpaired t test 
analysis), it is still difficult to conclude that the lower severity of disease was a result 
of adaptation and it may simply have been a feature of the reduced levels of cells 
present to mediate disease. The reduced expansion of the 4Tyr stimulated Tg4 cells 
may be a result of the lack of in vivo stimulation as exposure to the 4Lys peptide 
present in the CNS may not provide strong enough stimulation to maintain the 
transferred cells, if their sensitivity had been lowered in vitro.  
 
Further analysis showed no significant differences in Foxp3 expression of host or 
Tg4 cells in either group within the spleen. Both the host and transferred cells within 
the CNS of the 4Lys group had more than double the mean Foxp3 positive cells than 
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the 4Tyr group did (Fig. 5.11B). These differences would appear to rule out 
increased regulation within the CNS as a cause of reduced severity of disease in the 
4Tyr group. 
 
There was no significant difference in CD5 levels (p=0.7491; unpaired t test) that 
could help to explain the lower severity of disease in the 4Tyr groups, similar to 
observations from in vitro experiments (Fig. 5.12A). TCR levels did however appear 
significantly lower in this group compared to the 4Lys (p=0.0410; unpaired t test)  
and it is feasible that this mechanism acts to functionally desensitise the disease 
relevant cells, thereby ameliorating disease (Fig. 5.12B). 
 
 
5.7. Primary immunisation with 4Tyr ameliorates EAE induced with 4Lys 
peptide 
 
In order to examine whether a primary superagonist challenge would have a 
modulatory effect on a cell population subsequently challenged with the wild-type 
peptide, a double-immunisation protocol was used [269] (Fig 5.13A). Either 100µg 
4Lys or 100µg 4Tyr was introduced sub-cutaneously with CpG and IFA into 
C57BL/6 x B10.PL mice. Twenty-eight days later the mice were re-immunised with 
100µg 4Lys with CFA alongside to doses of PTx. This model was also used to 
investigate how long the effects of adaptive tolerance could be observed. Preliminary 
work had shown increases in CD5 expression after the primary immunisation with 
CpG and IFA hence these subsequent experiments assumed adaptive tolerance would 
be induced in these circumstances (data not shown). It should be noted that no Tg4 
cells were used in these initial experiments. 
 
Disease onset in the 4Lys immunised group was observed a mean of two days earlier 
than in the 4Tyr group and the mice in the latter group appeared to expand a cohort 
of T cells that were reduced in their efficacy of inducing EAE (Fig 5.13B). Only 50% 
of these mice showed clinical signs of EAE, with a mean maximum disease score of 
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one. Disease lasted a mean of 3 days in this group whereas the 4Lys mice still 
showed clinical signs 20 days after onset of disease (when they were culled having 
shown a mean 9.25 days of disease). The 4Lys group showed a mean maximum 
disease score of 2.5, with 75% of the mice showing signs of EAE. Mann-Whitney 
analysis showed the difference in disease burden to be highly significant with 
p<0.0001. 
 
Splenocytes were taken from the mice at day 27 and in vitro proliferation assays 
were performed using the 4Lys peptide. Cells from mice, immunised with 4Tyr 
where either no or low grade disease was observed, required there to be a 10-fold 
higher concentration of 4Lys to respond compared to those immunised with 4Lys 
(Fig 5.14A). The single mouse in which severe EAE was seen (maximum clinical 
score of 3) in the 4Tyr group showed a similar in vitro response to mice within the 
4Lys group (Fig 5.14B). 
 
A higher dose of 4Lys challenge was also required to induce production of IL-2 by 
these cells (Fig 5.14C). There appeared to be no defect in terms of the IFN-
γ production however, with both sets of cells produced similar levels of the cytokine 
upon challenge (Fig 5.14D). 
 
These data support the idea that the initial exposure to 4Tyr would be able to 
modulate subsequent disease course by adapting the 4Lys relevant repertoire of T 
cells by increasing their thresholds of proliferation and hence leaving them less 
susceptible to 4Lys challenge. There was no change in the sensitivity to IFN-γ 
production which may suggest that thresholds of activation were unaffected. In the 
4Tyr group where disease was seen in one mouse it may be feasible that either the 
initial dose of 4Tyr was not sufficient to adapt the 4Lys relevant T cell repertoire or 






5.8. 4Tyr Immunisation following a Primary 4Lys Immunisation fails to 
induce EAE  
 
To address how a diverse repertoire of T cells expanded by the primary 4Lys 
immunisation would react against a secondary stimulation with the superagonist 
4Tyr peptide, the previous experimental protocol was reversed. Mice were 
immunised initially with 4Lys, in CpG and IFA. This was followed by either 100µg 
4Lys, 100µg 4Tyr or 10µg 4Tyr, in CFA to induce EAE (Fig. 5.15A) with the 
disease course monitored for 23 days (Fig. 5.15B). 
 
No mice in the high dose 4Tyr immunisation group showed clinical signs of EAE. 
Disease onset in the 4Lys immunised group was seen two days later than in the 10µg 
4Tyr group. Only 60% of the mice in both these groups showed clinical signs of 
EAE, with the 10µg 4Tyr group having a mean maximum disease score of 2.4 
compared to a score of 1.8 in the 4Lys immunised group. Disease lasted an average 
of 6.2 days in the 10µg 4Tyr group whereas the 4Lys mice showed clinical signs for 
7.4 however disease between these two groups was shown not to be significant 
(Mann-Whitney analysis; p = 0.0696). 
 
Splenocytes were taken from the mice at day 23 and in vitro proliferation assays 
were performed against the 4Lys peptide (Fig. 5.16). Cells from the 100µg 4Tyr 
group showed limited proliferation against an in vitro challenge of 4Lys whereas 
10µg 4Tyr immunised splenocytes showed a similar proliferative potential to those 
from 4Lys immunised mice.  
 
 
5.9. Tracking Tg4 cells within the C57BL/6 X B10.PL adaptation model 
 
In order to track and observe behavioural and phenotypic responses in the relevant T 
cell repertoire during the process of adaptation 2x10
6
 Tg4 cells were transferred into 
the C57BL/6 x B10.PL double immunisation model (Fig 5.17A). As in previous 
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work (Fig 5.13), suppression of disease was seen in the groups that had received the 
4Tyr compared to the 4Lys as primary immunisation (Fig 5.17B & C). This 
suppression appeared to be linked to dosage; in groups where a higher dose of 4Tyr 
(200µg) was given almost total suppression of disease was seen (only 11.1% of the 
group - 2 out of 18 - showed clinical signs of EAE as opposed to 100% in the 4Lys 
group) (Fig 5.17B). When the peptide dose was halved, 66% of the 4Tyr group 
showed clinical signs of disease compared to 78% in the 4Lys groups (Fig 5.17C). 
The dose of 4Lys did not appear to make a difference to the peak of the mean clinical 
score between experiments however the higher dose did appear to prolong the 
disease course.  
 
Analysis of the transferred cells in the lymph nodes at seven days post primary 
immunisation showed similar levels of Tg4 cells (Fig. 5.18A). Phenotypic analysis of 
the Tg4 cells from the 4Tyr immunised groups showed that, although there was no 
difference in TCRβ expression (Fig. 5.18B), there was a significantly higher 
expression of CD5 than in the 4Lys immunised groups (Fig 5.18C; p = 0.0046). The 
increased CD5 levels in the 4Tyr group indicate that these Tg4 cells had adapted to 
the superagonist stimulus and this reduced sensitivity would explain a decreased 
pathogenic potential in vivo and the lower severity of disease. There was no 
significant difference in either CD44 (Fig 5.18D) or CD25 (Fig 5.18E) expression 
(p=0.4529 and p=0.5704 respectively; unpaired t test). Similar CD25 levels indicate 
no enhanced role for regulatory T cells with the caveat that Foxp3 analysis was not 
performed as part of these experiments as it was not deemed relevant at that time.  
 
When splenocytes from mice are examined at peak of disease after the secondary 
immunisation (day 14) the frequency of Tg4 cells is significantly higher in the 4Lys 
(Fig. 5.19A); with around double the frequency of cells present compared to the 4Tyr 
group (p=0.0054; unpaired t test). This significant difference is also observed in the 
levels of total CD4
+
 cells within the CNS (Fig 5.19B; p=0.0007; unpaired t test). 
However, Tg4 cells were not identifiable in the CNS at this time-point.  
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There was no significant difference in expression of TCR (Fig. 5.19C) or CD5 (Fig. 
5.12D) between the two groups (p=0.5230 and p=0.6135 respectively; unpaired t 
test) which could have helped to confirm the adapted state of the Tg4 cells present in 
the 4Tyr group.  
 
Data in this chapter show that in 4Tyr immunised mice, Tg4 cells do not track as 
effectively to the CNS as in 4Lys immunised mice. This may be reflective of the 
decreased numbers in the periphery but also because the 4Tyr is not presented within 
the CNS. CD44 levels in cells from the 4Tyr mice were significantly higher (Fig 
5.19E; p=0.0272) and this can be explained by the superagonist properties of the 
4Tyr peptide. This would indicate that it was not a failure of the 4Tyr antigen to 
activate the Tg4 cells that led to a reduction in disease severity. However the reduced 
numbers of cells in the spleen and CNS may thus be due to activation induced cell 
death caused by the potency of the 4Tyr peptide. 
 
Proliferation data from splenocytes (taken either at the peak of disease and after 
clinical signs have ceased) show that cells from 4Tyr immunised mice were defective 
in their ability to respond to the 4Lys peptide in vitro compared to cells from mice 
immunised with 4Lys (Fig 5.20). Bearing in mind that the initial in vivo 
immunisation was with 100µg of 4Tyr it would seem reasonable to extrapolate that 
the secondary in vivo stimulation of these cells with 100µg of 4Lys may not be 
enough to efficiently drive their expansion leading to less severe EAE, as seen in 














It has been proposed that the activation of auto-reactive T cells can be explained by 
two mechanisms; one of these, epitope spreading, was discussed in chapter 4; the 
second, molecular mimicry, is addressed by the series of experiments presented 
within this chapter. The data contained within this chapter indicate a role for 
adaptation as one the mechanisms of tolerance at play in ameliorating disease and 
maintaining a repertoire of disease relevant T cells. 
 
In line with previous work [174], the data within this chapter show that stimulation 
with a superagonist peptide (4Tyr) through immunisation is unable to induce disease 
when administered at the same dose as the wild-type (4Lys). However, if the dose of 
4Tyr was reduced 10-fold, compared to 4Lys, then the disease course induced was 
similar to that observed with the 4Lys. The fact that a reduction in the load of 4Tyr 
causes EAE would appear to uphold the tuneable activation threshold model; the 
cells will have received a lesser degree of stimulation with the lower dose and are 
therefore able to react against the 4Lys self-antigen present in the CNS. Data show 
that high doses of 4Tyr did not induce cell death of all the transferred Tg4 cells even 
by day 50 (Fig. 5.2A), hence the autoreactive repertoire of cells was maintained. The 
flow cytometry data indicate a role for CD5 and potentially adaptation in facilitating 
this, again agreeing with previous observations [174]. 
 
An interesting observation here is the increased level of effector cytokine activity 
from low dose 4Tyr immunised mice; there was an increase in the percentage of Tg4 
CD4
+
 cells recovered from these mice that produced either IFN-γ or IL-17, compared 
to those recovered from high dose 4Tyr or 4Lys immunised mice. This was seen 
even in the absence of in vitro peptide challenge and may explain why the low dose 




The work with Tg4 cells in vitro (Fig. 5.4) allowed the examination of the changing 
behaviour and phenotype of the cells in a far more simplified environment, compared 
to the in vivo situation, and free of non-relevant CD4
+
 cells. Again the data show a 
limitation in the pathogenic potential of Tg4 cells stimulated by high dose 4Tyr, 
whereas stimulation with low doses of 4Tyr produced cells with a similar pathogenic 
potential to 4Lys. A reduction in TCR expression and an increase in CD5 expression 
may both combine to allow T cells to reduce their functional sensitivity for 4Lys and 
thereby avoid AICD. Both of these observations are supported by previous studies, 
although what was not observed here was a reduction of CD4 expression, as seen 
elsewhere [283, 284]. Further work is also required to examine possible reductions in 
Ca
2+
 signalling and MAPK activation and the potential effects on the production of 
cytokines.  
 
The fact that, during the second and third rounds of stimulation, high dose 4Tyr 
stimulated cells were seen to respond to the 4Lys at 1µM supported the theory that it 
is selective pressure which pushes CD4
+
 cells to respond to antigen at this pre-
determined threshold; in this scenario the pressure having induced adaptation [159, 
260]. 
 
When these 4Tyr cultured cells were examined in vivo, using the passive transfer 
model (Figs. 5.8 & 5.9), at least two rounds of in vitro stimulation were required 
before their pathogenic potential was limited, compared to 4Lys stimulated Tg4 cells. 
This would support the idea that sustained stimulation is required for adaptation to 
occur. The pathogenic activity of cells exposed to a single round of 4Tyr stimulation 
may be explained by three factors; the cells found in the CNS may not have been 
fully adapted in vitro, adaptation may have been reversed when the superagonist 
stimulation was no longer present or the fact that cells were transferred immediately 
after the polarising conditions of the primary stimulation and prior to a rest period. 
 
The observation that 4Tyr mediated disease in the two round stimulation experiments 
is reduced in severity is clouded by the fact that the numbers of Tg4 cells recovered 
in the 4Tyr groups are halved compared to the 4Lys groups. This may be the 
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explanation for the difference in disease course seen mediated by the persistently 
stimulated cells.  The poor viability of the Tg4 cells in the 4Tyr high dose groups 
may be in turn be explained by the weaker stimulation they should receive in vivo 
from wild-type 4Lys presented in the CNS resulting in cell death. 
 
A dual-immunisation protocol enables the cross-reactive activation of auto-reactive T 
cells using the APL system. Unlike in previous experiments with the C57BL/6 x 
B10.PL mice, this chapter shows the manifestation of disease without the use of 
transgenic cells. There is pre-existing data that suggests that the repertoire of T cells 
expanded by the initial immunisation, the antigen-experienced cohort, are more 
liable to cause disease than the naïve cohort would have been [285]. This is largely 
due to less dependency for co-stimulation by B7 molecules and CD40. 
 
When 4Tyr was administered as a primary immunisation to be followed by 4Lys, the 
experiments attempted to mimic a scenario where T cells are activated by a strong 
stimulus from a foreign epitope followed by a weaker stimulus from a self epitope. 
The experiments show disease course was significantly decreased and splenocytes 
from these mice show a limited proliferative potential when challenged in vitro 
compared with cells from 4Lys primed mice. This supports the theory that antigen 
experienced cells tune themselves to a particular stimulus and that they require this 
level of stimulus to become activated again, at least for a certain period of time after 
the initial stimulus. The data here confirm previous observations in a PLP139-151 APL 
Y144/L144 model (where residue 144 is replaced by either tyrosine or leucine [286]) 
and show that IL-2 production is impaired in splenocytes from 4Tyr immunised mice 
compared to 4Lys groups whereas the level of IFN-γ produced is similar in both. 
There may be a mechanistic reason behind this: The factors controlling adaptation 
may only exert effects on the pathways which control the transcription of IL-2 and 
not those that control IFN-γ. This is however in contrast to data from Singh et al  




Accepting the caveat that they refer to this state of non-responsiveness as anergy 
rather than adaptation, Munder et al [286] explored the avenue of T cell signalling 
which was not investigated here. Activation of relevant T cells with Y144/L144 led 
to an unresponsiveness characterised by a dramatic reduction in tyrosine 
phosphorylation of TCR chains as well as a diminished Zap70 phosphorylation and 
Ca
2+
 signalling. These observations combine well with the theory that CD5 forms a 
complex with CD4 and Zap70 in adapted cells and that reduced levels of CD5 
correlate with increased levels of Ca
2+
 signalling and Zap70 phosphorylation [223, 
224]. This would appear to endorse the use of CD5 as one, of potentially multiple, 
marker of adaptation in these data. 
 
In the reverse scenario, where 4Tyr immunisation followed a 4Lys primary 
immunisation, the experiment mimics a scenario where an antigen experienced 
cohort of T cells is challenged subsequently with a much stronger stimulus. In these 
experiments no disease is observed after the high dose 4Tyr secondary immunisation. 
The low dose 4Tyr secondary immunisation group however showed similar disease 
to the 4Lys secondary immunisation group. Again, in terms of the level of 
stimulation provided to activate the T cells, the low dose 4Tyr provided a similar 
stimulus to the 4Lys. This highlights the potential for non-self peptides to promote 
disease by acting on a cohort of auto-aggressive cells expressing cross-reactive TCR. 
 
When transgenic cells were placed into this model, to enable clear tracking of the 
antigen-relevant cells, differences were evident mainly after the primary 
immunisation in cells taken from the lymph nodes. Once again it was the expression 
of the CD5 marker that was elevated on the 4Tyr stimulated cells with no other 
markers tested showing differences. Severity of disease was again reduced in the 
4Tyr immunised mice and although Tg4 numbers after disease may not reflect Tg4 
number during disease the differences in pathogenic potential of the cells may have 
been largely numerical. There were less than half the numbers of Tg4 cells in the 
spleen of 4Tyr immunised mice compared to the 4Lys immunised mice after disease. 
This may be a result of less stimulation for these cells throughout the 52 day 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6. General Discussion 
 
The experiments in this thesis use TCR transgenic models to explore two paradigms 
in autoimmune disease, namely epitope spreading and adaptive tolerance. Epitope 
spreading is the diversification of the immune system to an epitope distinct from the 
initiating epitope. Adaptive tolerance is based on the tuneable activation threshold 
model which suggests that a T cell repertoire with an autoreactive nature can tune its 
threshold for harm to prevent progression to an autoaggressive nature. 
 
 
6.1. The role of epitope spreading and the potential for bystander 
suppression in autoimmunity  
 
Epitope spreading is the concept used to explain the relapsing-remitting form of MS 
and EAE; predicting that the immune system’s focus against one epitope may cause 
damage in the target organ resulting in the release of cryptic self epitopes to which 
relevant effector T cells can react, thereby mediating a diversification of the immune 
response. The immune response to any of the epitopes involved may fade as disease 
progresses and this may make the identification of such epitopes more difficult. 
 
The data in Chapter 4 shows that the introduction of Tg4 cells into the B10.PLxSJL 
mouse has a pronounced effect on disease. Only in the presence of the Tg4 cells do 
the mice relapse into a secondary phase of disease and yet none of the ex vivo data 
show cell response against the 4Lys peptide, nor does flow cytometric data show the 
presence of Tg4 cells in the CNS of sick mice. It is possible that the response of the 
immune system to the MBPAc1-9 epitope may be imperceptible to our detection 
techniques, or that the response may fade rapidly and spread to other epitopes. Data 
in Chapter 4 showing pathogenicity of the MBPAc1-9 epitope  in B10.PL x SJL mice 
are consistent with  previous findings showing that the epitope causes RR-EAE 
[265]. This suggests that relevant MBPAc1-9 T cells must have the capacity to travel 
into the CNS of these mice and that perhaps the chosen timing of the analysis 
looking for the cells in the data shown here was unfortunate. Further investigation of 
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this mouse, with PLP139-151 immunisation and Tg4 adoptive transfer is required, prior 
to relapse, at the peak of each phase of disease and during recovery periods to 
address whether reactivity can be detected from cells in the lymph nodes, spleen and 
the CNS; cell infiltration into the CNS must also be confirmed.  
 
It therefore stands to reason that the epitope hierarchy in spreading within this model 
must be investigated. If the immune response to MBPAc1-9 does fade rapidly then the 
epitopes to which the immune response diverts to must be identified. Previous data in 
the SJL mouse show that PLP139-151 immunisation resulted in RR-EAE in which the 
hierarchy spread intramolecularly to a primary relapse against PLP178-191 and then 
intermolecularly, for a second relapse against the MBP84-104 epitope [267]. 
Intramolecular spreading in the B10.PL x SJL mouse was seen by Lehmann et al 
[265]. Splenocytes from these mice were shown to have recall responses against 
MBP epitopes 35-47, 81-100 and 121-140. An effective strategy to address the 
hierarchy question would involve ex vivo proliferation assays against all the epitopes 
mentioned above at several time points during disease, prior to, during and in 
recovery of each phase of disease.  
 
Bystander suppression occurs when regulatory T cells are generated relevant to one 
epitope but have the potential to regulate or suppress disease mediated by cells 
relevant to a different non-structurally related epitope that is present within the same 
organ or tissue. Hence the diversification of the immune response seen in epitope 
spreading may be advantageous if regulatory T cells relevant to revealed epitopes 
can be used to down regulate disease directed against another epitope. The 
experiments shown in Chapter 4 use the 4Tyr APL of MBPAc1-9 with PBS within the 
Tg4 cell / B10.PLxSJL model prior to the induction of EAE with PLP139-151 and 
CFA. The data show the absence of a relapse between days 20 and 45 in the 4Tyr 
treated mice. Further analysis of tissues shows that not only are Tg4 cells enriched 
within the CNS samples but that 45% of these cells expressed the regulatory T cell 
marker, Foxp3.  
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The data shown, however, do not address the question of whether the 4Tyr induced 
regulatory Tg4 cells are mediating bystander suppression in this model. No data 
assessing cytokine production of these cells were collated and therefore it cannot be 
discerned whether Tg4 Foxp3
+
 cells have a direct role, through the production of IL-
10 or TGF-β, in the down-regulation of pathogenicity of disease relevant effector T 
cells. Again, a major caveat here is the absence of evidence showing T cell reactivity 
against 4Lys in ex vivo assessments. 
 
One serious critique of these experiments may be the difference in time points of the 
introduction of Tg4 cells (Figure 4.6A). Control mice not receiving 4Tyr were given 
Tg4 cell transfer 6 days after mice that did receive 4Tyr treatment. This was justified 
due to concerns about the viability of Tg4 cells in the B10.PL x SJL mouse in the 
absence of TCR stimulation. 
 
Experiments must be planned to address whether 4Tyr exposed / induced regulatory 
Tg4 cells are able to effectively suppress disease induced with epitopes other than 
PLP139-151. This can be simply addressed by immunisation with whole myelin. 
 
The role of the APC must also be examined. Recent data suggest that three 
populations of DCs are recruited into the CNS from the periphery during acute 
phases of disease in relapsing-remitting EAE; mDCs, pDCs and CD8α DCs [287]. It 
may be possible that one subset of DC is more efficient as APC for an effective T 
cell response to MBP [119] and another subset is more efficient for PLP139-151. In that 
scenario, Tg4 cells migrating to the CNS may therefore be left at a disadvantage. 
Firstly the immune response in the PLP139-151 immunised model would encourage the 
active recruitment of PLP relevant DC to the CNS; secondly the cytokine milieu 
created by that subset of DC may negatively affect the antigen presenting capacity of 
another group of APC needed to mediate MBP relevant disease. It stands to reason 
that if certain APC are essential in epitope spreading then others may be crucial in 
the induction of bystander suppression. This in turn brings us to the role of cytokines 
in RR-EAE; what is the ideal cytokine milieu for epitope spreading to occur? 
Cytokine production from CNS cell infiltrate also needs to be investigated.  
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Bystander suppression may be the answer to the how T cells can be tolerised against 
known and unknown epitopes in autoimmune disease. If regulatory T cells can be 
produced against a key disease relevant epitope then they may afford the control of 
disease that is directed against any epitope.  
 
 
6.2. Investigating T cell tuning with a molecular mimicry model of disease 
 
The experiments presented in this thesis used APL to assess how a state of tolerance 
may be both maintained and potentially broken by molecular mimicry. The APL / 
EAE model does not allow the evaluation of microbially-derived epitopes. However 
it does help to elucidate the mechanisms behind the molecular mimicry based 
initiation of autoimmune disease as well as disease events after such an initiation. 
This, in turn, will help to design strategies for the treatment and prevention of 
autoimmune diseases. 
 
The suggestion that antigenic determinants of micro organisms, specifically 
parasites, resembled antigenic determinants of hosts was first made in the 1960s by 
Damian et al [288]. This molecular mimicry concept was initially used to explain 
how parasites evaded host immune responses to survive and was later modified to 
suggest immune responses against a pathogenic epitope could at a later time point 
develop into autoaggressive responses through recognition of host epitopes bearing 
structural or sequence homology to the pathogenic epitope [228]; with the initiating 
event and autoimmune onset separated temporally and spatially.  
 
Although the MBPAc1-9 APL model is limited by differences in disease induced by 
the various APL, it can be used to mimic a situation where a relevant T cell 
repertoire has been challenged by a microbial epitope giving a strong stimulus (4Tyr) 
to relevant T cells. These T cells can, at a later time point, be challenged by weaker 
stimulation with a self epitope (4Lys) bearing structural homology to the initiating 
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epitope. This could also be reversed to model a scenario where an antigen 
experienced repertoire of T cells is created by a foreign epitope (4Lys) giving a weak 
signal to the TCR and then stimulated by a self epitope giving a much stronger 
stimulus (4Tyr). 
 
Wucherpfennig and Strominger searched for structural homology between viral and 
bacterial peptides by analysing epitopes in which TCR-binding amino acid residues 
were similar to those from MBP. From a panel of 129 epitopes identified and tested 
on seven MBP-relevant T cell clones, from MS patients, seven viral epitopes and one 
bacterial epitope were able to activate three of the clones. Interestingly, only one 
epitope could have been identified through sequence alignment [232]. The clearest 
example of molecular mimicry in a model of MS is shown in the series of work using 
Theiler’s virus genetically modified to express epitopes activating PLP relevant T 
cells [52, 55, 277] and has been previously discussed (Section 1.3). EAE 
investigations have found that homology between microbe and mimic do not have to 
be extensive, with a polyalanine peptide sharing only 4 residues with MBPAc1-9 able 
to induce EAE in PLSJL/J F1 mice [289]. Semliki Forest virus and MOG epitopes 
have also been shown to show homology and induce MS-like disease through this 
mimicry [290]. Antiserum against MBP110-124 shows reactivity against Pseudomonas 
peptides as well as against Acineobacter peptides, antiserum against MOG43-57 also 
showed reactivity against Acineobacter peptides [291]. 
 
The work shown here examines molecular mimicry in the setting of adaptive 
tolerance using a simple model based on immunisation with peptides and APL rather 
than infection. The investigation is built on previous work which highlights the effect 
of superagonists [174, 261]. Adaptive tolerance may be an appealing option for the 
immune system compared to cell death because the reversibility of the state affords 
the option to maintain a diverse T cell repertoire; it is a repertoire that is kept below a 
threshold for harm.  Reversibility allows the maintenance of disease relevant T cells 
which may bear cross-reactive TCR needed at a later time-point for responses to 
microbial epitopes. Paradoxically, reversibility may be the Achilles' heel of adaptive 
tolerance; if a microbial epitope is able to expand a large population of autoreactive 
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T cells which are adapted then, after a period of time when the cells regress from the 
adapted state, they could become autoaggressive and react against self-peptides 
which mimic the initiating peptide. This is dependent, however, on a later insult to 
the target organ. In the case of MS and EAE, a requirement of perturbation of the 
blood brain barrier and insult to the CNS.  
 
The data shown here indicate the potential for APL to prevent autoimmune disease 
by inducing adaptive tolerance amongst autoreactive cells and thereby preventing 
them from becoming autoaggressive. There are several caveats to the data shown 
here, primarily that the other two key mechanisms of tolerance are not fully ruled 
out. The effects of the Fas / FasL mediated AICD and the capacities of regulatory T 
cells have not been eliminated from the analysis. The possibility that the culture 
conditions merely help to select a distinct TCR bearing repertoire from the Tg4 CD4
+
 
population used is also yet to be eliminated. Several attempts were made to address 
these issues; experimental procedures outlined in Figure 5.4 were attempted in a 
more simplistic form, using only 1mM 4Lys and 1mM 4Tyr in vitro stimulations, to 
compare changes in ‘normal’ Tg4, Tg4 lpr  (mutant Fas deficient mice) and Tg4 
RAG
-/-
 mice.  
 
Tg4 lpr mice allow the exclusion of AICD due to their Fas deficiency and would 
allow determination of whether adaptation alone is sufficient to limit the pathogenic 
potential of disease relevant cells. These mice could also be used to investigate 
whether cells with low expression of CD5 are merely deleted from the repertoire 
leaving only cells with high CD5 expression or if in fact de novo increases in CD5 
expression occurs on adapted cells in line with the level of stimulus received in the 
immediate environment. If CD5 expression increases upon 4Tyr stimulation in Tg4 
lpr cells then it would suggest that adaptation is accompanied by an increase in CD5 
expression. If only a small number of Tg4 lpr cells express CD5 then it could be 
suggested that the elevation of CD5 shown in the data within this thesis is a result of 
the loss of Tg4 cells with low expression of CD5.  
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Theoretically, Tg4 cells bear a moderate affinity TCR for 4Lys. However, unless 
these mice are crossed onto the RAG
-/-
 background, the possibility of different 
repertoires of Tg4 cells bearing different affinity TCR for 4Lys still exists. RAG 
sufficient Tg4 cells may have the ability to express alternative α or β chains. The 
Tg4 RAG
-/-
 mice allow the confirmation that 4Tyr limits the pathogenicity of the Tg4 
cell repertoire towards 4Lys through adaptation rather than selection of low affinity 
TCR bearing Tg4 cells which bind poorly to 4Lys-MHC complexes. It was not 
possible, however, to keep either Tg4 lpr or Tg4 RAG
-/-
 cells alive within cultures, 
regardless of stimulating peptide. This may be explained by the poor conditions of 
the animal unit in which these mice were kept. Cells from Tg4 mice which were kept 
in a separate unit did not present with the same problems.  
 
It appears that only Schwartz’s original demonstration of adaptation [219], using 
RAG
-/-
 transgenic peptide relevant cell transfers into CD3ε-/- mice have been able to 
rule out the effect of regulation and the selection of distinct repertoires; as this is the 
only in vivo adaptation model that uses only antigen relevant T cells of the RAG
-/-
 
background and can therefore preclude the host T cells from the analysis.  
 
This system also shows an increase in CD5 expression in CD4
+
 T cells following the 
induction of tolerance; these studies associate CD5 with the SHP-1 signalling 
molecule. CD5 expression has also been used as a part of the analysis of an adaptive 
state within the experiments shown here. The majority of the data here show that T 
cell unresponsiveness correlates with an increase in CD5 expression. However the 
role of this glycoprotein is not fully clarified. Previous data has highlighted a role for 
CD5 within the EAE model. Elevated CD5 expression is associated with T cell 
unresponsiveness when MOG35-55 is presented by steady-state DC [281] and 
apoptosis of disease-relevant cells is increased in the absence of inhibitory signals 
from CD5 in knockout mice to suppress EAE [282]. These and other data show a 
negative regulatory role for CD5 in T cell activation [292] which is mediated by the 
cytoplasmic region [293] independently of extracellular engagement [294]. CD5 has 
also been implicated in studies of adaptive tolerance with CD8
+
 cells [295]. 
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CD5 is upregulated alongside CD6 and CD2 on activated T cells. CD5 shares 
similarities with the CD6 molecule also, for example both contain several tyrosine 
residues in their cytoplasmic regions. An interesting avenue of exploration is the role 
of CD6 alongside CD5 as CD6 interacts with the CD166 ligand to reduce IL-2 
production and has also been shown to interact with the SLP-76 SH2 domain. The 
elevation of CD6 on activated T cells results in unresponsiveness of T cells in a 
similar fashion to CD5 [296]. Even if CD5 proves to be important in our studies of 
MBPAc1-9 APL, it may eventuate that CD5 may not be required for adaptation in 
other models of disease or even within other models of EAE. 
 
Previously the use of APL in models of EAE has resulted in the deviation of Th1 
responses to Th2 responses. The L144/R147 analogue of PLP139-151 was used to 
antagonise TCR and thereby prevent the activation of Th1 cells by polarising cells to 
a Th2 subtype. Primary immunisation with this analogue prevented EAE induced 
with a secondary immunisation with PLP, MOG and MBP [297]. APL of MBP87-99 
have been also shown to ameliorate EAE by deviating a Th1 response to Th2 in mice 
and rats [267]. APL for the same region of MBP have been shown to prevent the 
production of IL-2, IFN-γ, IL-4, IL-10 and yet induce the production of TGF-β1. 
Investigations as part of the work shown in this thesis conflicted with previous work 
by Pearson et al which suggested that 4Tyr stimulation of MBP-specific TCR 
transgenic resulted in Th2 deviation of the immune response characterised by 
production of IL-4 [298]. No deviation towards a Th2 phenotype could be detected in 
the course of this work; Tg4 cells were stimulated with superagonist 4Tyr in vitro 
and IL-4 production could not be detected by either supernatant ELISA or flow 
cytometry (intracellular cytokine staining). 
 
There are still some outstanding questions regarding the exact role and contributions 
of adaptive tolerance in limiting the autoaggressive potential of autoreactive T cells. 
What are the contributing mechanisms for adaptation or is there a single mechanism? 
How long does the state of adapted tolerance last and what factors cause variations in 




The APL based therapies shown in this thesis are within relatively simple systems. 
The translation of these therapies into human disease may be prohibitively complex 
and require extreme caution. APL studies are advantageous, however, in determining 
which disease relevant cells are more prone to tolerisation and in addressing the role 
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